Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Maryland
Clinical trial register · United States · industry-sponsored

Clinical Trials in Maryland, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9118 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Oct 2026, 03:16 UTC
9118
Studies in scope
industry-sponsored, all four open statuses
4945
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 5290 Florida 4430 Illinois 2481 Georgia 2368 Arizona 2238
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca78 Novartis Pharmaceuticals31 Merck Sharp & Dohme LLC29 Eli Lilly and Company28 Pfizer27
State
California5290 Florida4430 Illinois2481 Georgia2368 Arizona2238
All 51 states
Target enrolment
to

Trials with a site in Maryland

1268 of 9118 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Safety Study of XT-150 in Participants With ALS
NCT06704347Amyotrophic Lateral Sclerosis (ALS)
Xalud Therapeutics, Inc.
Phase 1
8
Arizona, Maryland, Massachusetts, Michigan
2027-03
Not yet open
Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults
NCT07831473Randomised Clinical Trial, Double Blind, Dengue, Challenge Test
VLP Therapeutics
Phase 1
42
Maryland
2027-01-04
Not yet open
A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides
NCT07714187Mycosis Fungoides, Cutaneous T-cell Lymphoma
DrugDuvelisib
SecuraBio
Phase 1
30
Maryland
2027-01
Not yet open
Multi-Modal Digital Monitoring of Disease Symptoms in Spinocerebellar Ataxia
NCT07851376Spinocerebellar Ataxia (SCA)
BioSensics
Observational
25
Maryland, New York
2026-12-15
Not yet open
XVIE to Treat Androgenetic Alopecia (AGA)
NCT07482423Androgenetic Alopecia
Restore Biologics Holdings, Inc. dba Xtressé
Phase 1/2
30
Florida, Maryland
2026-12-01
Recruiting
A Pivotal Clinical Study to Evaluate the MySalvia System for the Treatment of Resistant Migraine
NCT07719608Resistant Migraine, Chronic Migraine Headache, Headache (Migraine), Headache, Cluster
Salvia BioElectronics
Not applicable
150
Georgia, Maryland, North Carolina
2026-12-01
Not yet open
The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma
NCT07386002Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
T-MAXIMUM Pharmaceutical Inc
Phase 2
40
Maryland
2026-11-30
Not yet open
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
NCT07789015Idiopathic Inflammatory Myopathies
DrugNerandomilast
Boehringer Ingelheim
Phase 3
270
Arizona, California, Colorado, Florida, Kansas, Maryland, Massachusetts, Michigan
2026-11-09
Not yet open
A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder
NCT07772531Major Depressive Disorder
Bristol-Myers Squibb
Phase 2
200
Arizona, Arkansas, California, Florida, Georgia, Maryland, Massachusetts, New York
2026-10-30
Not yet open
A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant
NCT07613359Antibody-Mediated Rejection (AMR)
DrugMezagitamab
Takeda
Phase 2
36
California, Florida, Maryland, Missouri, New Jersey, New York, Ohio, Texas
2026-10-15
Not yet open
Clinical Evaluation of an Alarm Activated Detection System to Enable Early Intervention of Emerging Respiratory Decline With the Linshom Medical Continuous Predictive Respiratory Sensor (CPRS)
NCT07793981Post Surgical Respiratory Failure, Respiratory Complication, Opioid Induced Respiratory Depression, Respiratory Arrest
Linshom Medical, Inc.
Not applicable
394
Maryland, Ohio
2026-10-01
Recruiting
A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.
NCT07559175Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality, Pancreatic Diseases
DrugZenpep
Aimmune Nestlé Health Science US R&D, LLC
Phase 2
66
Arizona, Arkansas, California, Florida, Kansas, Maryland, Montana, Ohio
2026-10
Not yet open
A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )
NCT07526974Subcutaneous Fat
DrugCBL-514
Caliway Biopharmaceuticals Co., Ltd.
Phase 3
320
California, Florida, Georgia, Maryland, Nebraska, New York, Ohio, Tennessee
2026-10
Recruiting
To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome
NCT06840496Rett Syndrome
Biomed Industries, Inc.
Phase 3
210
Arizona, California, Colorado, Florida, Illinois, Maryland, Massachusetts, New York
2026-09-30
Not yet open
An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
NCT07807969Geographic Atrophy
DrugVonaprument
Annexon, Inc.
Phase 3
605
Florida, Maryland, Massachusetts, North Carolina, Oregon
2026-09-30
Not yet open
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
NCT07680790Non-Small Cell Lung Cancer
DrugsIza-bren·Osimertinib·Pemetrexed·Cisplatin
Bristol-Myers Squibb
Phase 3
850
California, Colorado, Florida, Hawaii, Illinois, Maryland, Minnesota, Missouri
2026-09-30
Not yet open
Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer
NCT07808151Colon Cancer, Microsatellite Stable (MSS) Colon Cancer, Proficient Mismatch Repair (pMMR) Colon Cancer
DrugsPorustobart·Keytruda·Pembrolizumab
Solstice Oncology, Inc.
Phase 2
100
California, Florida, Illinois, Maryland, Massachusetts, New York, Ohio, Tennessee
2026-09-30
Recruiting
A Study of Amicidin-β Topical Solution for Patients With Surgical or Traumatic Wound Infections
NCT07379684Surgical Wound Infection, Traumatic Wound Infection
Macro Biologics, Inc.
Phase 1
44
California, Idaho, Maryland, Missouri, Ohio
2026-09-30
Not yet open
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication
NCT07855133Overweight, Obesity, Type 2 Diabetes
DrugsZenagamtide·Semaglutide
Novo Nordisk A/S
Phase 1
60
California, Maryland
2026-09-30
Not yet open
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
NCT07816666Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
DrugsTorvutatug samrotecan·Bevacizumab
AstraZeneca
Phase 3
600
Alaska, Maryland, Michigan, New York, Ohio, Pennsylvania, West Virginia
2026-09-29
Recruiting
A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury
NCT07799532Chronic Spinal Cord Injury
NervGen Pharma
Phase 3
150
Alabama, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Maryland
2026-09-28
Recruiting
An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin
NCT07845071Pain
Adneuris Therapeutics, Inc.
Phase 3
160
Arizona, California, Colorado, Georgia, Illinois, Maryland, New Jersey, Oklahoma
2026-09-22
Not yet open
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
NCT07768189Oropharyngeal Carcinoma (OPC)
DrugsCRB-701·Cetuximab·Docetaxel
Corbus Pharmaceuticals Inc.
Phase 3
260
Arizona, California, Colorado, Connecticut, Florida, Illinois, Iowa, Maryland
2026-09-20
Not yet open
A Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics
NCT07371429Urinary Tract Infections
DrugGepotidacin
GlaxoSmithKline
Phase 1
25
California, Louisiana, Maryland, Missouri
2026-09-18
Recruiting
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
NCT07851025Epithelial Ovarian Cancer
DrugsTorvutatug samrotecan·Bevacizumab
AstraZeneca
Phase 3
950
Florida, Maryland, Montana, Ohio
2026-09-16
Recruiting
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
NCT07648264Secondary Immune Deficiency
DrugHizentra
CSL Behring
Phase 3
63
California, Colorado, Florida, Indiana, Maryland, New Jersey, New York, North Carolina
2026-09-15
Recruiting
A Study in Adults With Geographic Atrophy
NCT07606365Geographic Atrophy
DrugSTL303
Sitala Bio LTD
Phase 2
300
California, Colorado, Connecticut, Illinois, Maryland, Massachusetts, New York, Pennsylvania
2026-09-11
Recruiting
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia
NCT07619118Hypercholesterolaemia
DrugsRosuvastatin 1·Rosuvastatin 2
AstraZeneca
Phase 3
200
Arizona, California, Florida, Georgia, Indiana, Louisiana, Maryland, North Carolina
2026-09-10
Recruiting
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07680764Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
DrugsImzokitug·Vedolizumab·Infliximab·Pumitamig
Bristol-Myers Squibb
Phase 2
160
District of Columbia, Georgia, Kentucky, Maryland, Mississippi, Nebraska, New York, Ohio
2026-09-10
Not yet open
Hypoxic Red Blood Cells in Sickle Cell Anemia
NCT06743113Sickle Cell Anaemia, Sickle Cell Anemia Crisis, Sickle Cell Anemia in Children, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Hemanext
Not applicable
48
Connecticut, Georgia, Illinois, Maryland, Pennsylvania
2026-09-01
Recruiting
A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat
NCT07140939Subcutaneous Fat
DrugCBL-514
Caliway Biopharmaceuticals Co., Ltd.
Phase 3
320
California, Florida, Illinois, Louisiana, Maryland, Nebraska, New Jersey, New York
2026-09-01
Recruiting
Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions
NCT07654283Hepatitis B, Chronic
DrugAHB-137
AusperBio Therapeutics Inc.
Phase 2
70
California, Maryland, New York, Texas
2026-09-01
Not yet open
A Comparison of Cosmos Rx Medication Adherence Platform vs. Pharmacy Fill Adherence Measures
NCT07712614GERD (Gastroesophageal Reflux Disease)
Cosmos Rx, Inc
Not applicable
50
Maryland
2026-09-01
Recruiting
A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
NCT07804615PARKINSON DISEASE (Disorder)
DrugVIM0423
Vima Therapeutics
Phase 2
80
Arizona, California, Connecticut, Florida, Georgia, Kansas, Maryland, Michigan
2026-09
Not yet open
WATER IV PCa (AS Sub-study)
NCT07650448Localized Prostate Cancer
PROCEPT BioRobotics
Not applicable
333
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Maryland
2026-09
Not yet open
A Trial to Assess the Safety and Effectiveness of an Anatomic Total Shoulder System
NCT07812324Shoulder Arthroplasty, Total Shoulder Arthroplasty
Medacta USA
Not applicable
286
Arizona, Florida, Indiana, Maryland, New Hampshire, New York, Oregon, Pennsylvania
2026-09
Recruiting
Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC
NCT07722741HCC
DrugsGNOS-PV02·INO-9012
Geneos Therapeutics
Phase 2
90
Georgia, Louisiana, Maryland, Michigan, New York, Texas, Washington
2026-09
Recruiting
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
NCT07705555Diabetic Retinopathy, Macular Edema
DrugsTiespectus·Eylea·Aflibercept
Merck Sharp & Dohme LLC
Phase 3
960
California, Colorado, Florida, Maryland, New Jersey, New York, North Carolina, South Carolina
2026-08-27
Recruiting
A 52-week Study of Remibrutinib in IgE-mediated Food Allergy
NCT07768371IgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy, Egg Allergy
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
576
Alabama, Arizona, Arkansas, California, Georgia, Illinois, Maryland, Michigan
2026-08-27
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight
NCT07842640Chronic Weight Management
DrugTirzepatide
Ascletis Pharma (China) Co., Limited
Phase 1
84
Maryland
2026-08-27
Recruiting
A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
NCT07771465Symptomatic Genetic Dilated Cardiomyopathy (DCM)
DrugDanicamtiv
Kardigan, Inc.
Phase 3
332
Alabama, California, District of Columbia, Florida, Illinois, Louisiana, Maryland, Massachusetts
2026-08-26
Recruiting
A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
NCT07795814Heart Failure With Preserved Ejection Fraction
Edgewise Therapeutics, Inc.
Phase 2
90
Alabama, California, Illinois, Indiana, Kentucky, Louisiana, Maryland, Michigan
2026-08-25
Recruiting
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
NCT07776509Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2
DrugLenbelintide
AstraZeneca
Phase 3
500
California, Florida, Georgia, Illinois, Maryland, Missouri, Nevada, New Jersey
2026-08-24
Recruiting
Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel
NCT07765446Chemotherapy-induced Peripheral Neuropathy
Sironax USA, Inc.
Phase 2
18
Florida, Maryland, New Jersey
2026-08-21
Recruiting
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
NCT07686263Schizophrenia
DrugKarXT
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
472
Arkansas, California, Florida, Georgia, Illinois, Maryland, Ohio, Oklahoma
2026-08-20
Recruiting
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
NCT07812805Selected Advanced Solid Tumors, Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Biliary Tract Cancer (BTC)
SK Life Science, Inc.
Phase 1
100
Maryland, Pennsylvania
2026-08-19
Recruiting
This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC
NCT07723924Functional Constipation (FC)
Bausch Health Americas, Inc.
Phase 2
180
Alabama, Arkansas, California, Florida, Georgia, Kansas, Louisiana, Maryland
2026-08-18
Recruiting
Mobile Technology to Reduce Teen Substance Misuse
NCT05897164Substance Use, Substance Abuse, Suicide, Adolescent
Evidence-Based Practice Institute, Seattle, WA
Not applicable
600
Maryland, Washington
2026-08-18
Recruiting
Pivotal Study of N-acetyl-L-leucine for CACNA1A
NCT07221292CACNA1A, Spinocerebellar Ataxia Type 6, Episodic Ataxia Type 2, Familial Hemiplegic Migraine-1
DrugN-Acetyl-L-Leucine
IntraBio Inc
Phase 3
60
Maryland, Massachusetts, Texas
2026-08-17
Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
NCT07775300Depressive Disorder, Major
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,000
Alabama, Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts
2026-08-14
Recruiting
Evaluate the Effectiveness and Safety of BBD-1 Multi-target Immune Enhancement Targeting Agent in the Treatment of Hypersensitivity Reaction (IgA) Vasculitis
NCT07595367Allergic Reaction (IgA) Vasculitis
Qifeng Zhang
Phase 2
30
Maryland
2026-08-10
Recruiting
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
NCT07626411Atrial Fibrillation (AF)
DrugsCenvacibart·Apixaban
Regeneron Pharmaceuticals
Phase 3
15,364
Alabama, Arizona, California, Florida, Georgia, Indiana, Louisiana, Maryland
2026-08-10
Recruiting
A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication
NCT07612267Lactation, Inflammatory Bowel Disease
DrugMirikizumab
Eli Lilly and Company
Phase 4
14
Illinois, Iowa, Maryland, New York, Ohio
2026-08-05
Recruiting
A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia
NCT07734493Schizophrenia
Leal Therapeutics, Inc
Phase 1
90
Arkansas, California, Florida, Georgia, Maryland, New Jersey, Texas
2026-08-03
Recruiting
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO
NCT07734844Diabetic Macular Edema (DME)
DrugsTabirafusp tedromer·Eylea·Aflibercept
Kodiak Sciences Inc
Phase 3
910
California, Florida, Maryland, Minnesota, South Carolina
2026-08-03
Not yet open
A Wearable Sensor Platform for Remote Monitoring of Individuals on the Frontotemporal Dementia Spectrum
NCT07569367Frontotemporal Lobar Degeneration (FTLD), Frontotemporal Dementia (FTD), Corticobasal Degeneration, Corticobasal Syndrome (CBS)
BioSensics
Observational
60
Maryland, Massachusetts
2026-08-01
Recruiting
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
NCT07745361Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer, Prostate Cancer, Prostate Cancer (Adenocarcinoma)
DrugsMRT-2359·Apalutamide
Monte Rosa Therapeutics, Inc
Phase 2
25
California, Colorado, Kansas, Maryland, Michigan, Nebraska, New Jersey, North Carolina
2026-08
Recruiting
A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old
NCT07722546Graves' Disease
DrugFelzartamab
Biogen
Phase 2
60
Arizona, California, Florida, Maryland, North Carolina, Texas
2026-07-30
Recruiting
A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
NCT07733765Alopecia Areata
DrugRitlecitinib
Pfizer
Phase 3
336
California, Florida, Illinois, Indiana, Iowa, Maryland, Michigan, North Carolina
2026-07-30
Recruiting
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
NCT07684144Obesity, Overweight, Diabetes Mellitus, Type 2
DrugMaridebart cafraglutide
Amgen
Phase 3
950
Arizona, California, Florida, Illinois, Iowa, Kansas, Louisiana, Maryland
2026-07-29
Recruiting
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
NCT07723833Healthy Participants
AstraZeneca
Phase 1
152
California, Maryland
2026-07-27
Recruiting
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
NCT07585266Gastrointestinal Stromal Neoplasms
DrugsVelzatinib·Imatinib
GlaxoSmithKline
Phase 3
800
Arizona, California, Connecticut, Maryland, Nebraska, New York, Ohio, Tennessee
2026-07-27
Recruiting
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
NCT07492680Solid Tumors
DrugsNavlimetostat·Pumitamig·Temozolomide·Cetuximab
Bristol-Myers Squibb
Phase 2
260
California, Colorado, Georgia, Maryland, Massachusetts, Michigan, Minnesota, New York
2026-07-27
Recruiting
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
NCT07444567Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
DrugsFasenra·Benralizumab
AstraZeneca
Phase 3
230
Colorado, Maryland, Michigan, New Jersey, New York, North Carolina, Ohio, Utah
2026-07-24
Recruiting
DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.
NCT07635563Obstructive Sleep Apnea (OSA)
DrugAcetazolamide
Incannex Healthcare Ltd
Phase 2
120
California, Florida, Louisiana, Maryland, Ohio, South Carolina, Tennessee, Texas
2026-07-21
Recruiting
A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)
NCT07366034Fibrosing Interstitial Lung Disease
DrugNerandomilast
Boehringer Ingelheim
Phase 3
35
California, Colorado, Maryland, Massachusetts, Minnesota, Ohio, Pennsylvania
2026-07-21
Recruiting
A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications
NCT07330258Parkinson's Disease
Bayer
Observational
300
Arizona, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts
2026-07-21
Recruiting
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
NCT07609940Relapsed/Refractory Multiple Myeloma (RRMM)
DrugsLinvoseltamab·Tocilizumab
Regeneron Pharmaceuticals
Phase 4
30
California, Florida, Louisiana, Maryland, Washington
2026-07-15
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)
DrugsObrixtamig·Etoposide·Carboplatin
Boehringer Ingelheim
Phase 3
390
Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Minnesota
2026-07-10
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
NCT07664553Type 2 Diabetes Mellitus
DrugElecoglipron
AstraZeneca
Phase 3
600
Arkansas, California, Colorado, Florida, Georgia, Maryland, New York, North Carolina
2026-07-08
Recruiting
Pridopidine Phase 3 Study in Huntington's Disease
NCT07609108Huntington Disease
DrugPridopidine
Prilenia
Phase 3
400
Alabama, California, District of Columbia, Florida, Illinois, Kansas, Maryland, Massachusetts
2026-07-01
Recruiting
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
NCT07453888Non-Arteritic Anterior Ischemic Optic Neuropathy
DrugCenegermin
Dompé Farmaceutici S.p.A
Phase 3
272
California, Colorado, Florida, Georgia, Illinois, Kentucky, Maryland, Massachusetts
2026-07-01
Not yet open
Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated Hemorrhage
NCT07218185Hypofibrinogenemia, Hemorrhage, Trauma Associated Hemorrhage, Hemorrhagic Shock
Cerus Corporation
Observational
320
Colorado, Florida, Maryland, Missouri
2026-07
Recruiting
A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)
NCT07614984Lipoprotein(a)
DrugsHRS-5346·Enlicitide
Merck Sharp & Dohme LLC
Phase 2
750
Alabama, California, Connecticut, Florida, Maryland, Michigan, Minnesota, Montana
2026-06-30
Recruiting
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
NCT07650916HIV Infections
DrugsCab Ula·Rpv La·Cabotegravir
ViiV Healthcare
Phase 3
564
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Maryland, Michigan
2026-06-25
Recruiting
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
NCT07621237Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Depression
DrugCyclobenzaprine
Tonix Pharmaceuticals, Inc.
Phase 2
360
Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland, Massachusetts
2026-06-25
Recruiting
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
NCT07668388Diabetes Mellitus, Type 2
DrugsUBT251·Semaglutide
Novo Nordisk A/S
Phase 2
300
Alabama, California, Florida, Indiana, Kansas, Maryland, North Carolina, North Dakota
2026-06-22
Recruiting
Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder
NCT07644052Cannabis Withdrawal
DrugNabilone
PleoPharma, Inc.
Phase 3
420
Arkansas, Connecticut, Florida, Georgia, Kentucky, Maryland, Nevada, New Jersey
2026-06-17
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
NCT07644559Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS
DrugsVS-7375·Cetuximab
Verastem, Inc.
Phase 2
180
California, Florida, Maryland, Massachusetts, Michigan, Minnesota, Missouri, New Jersey
2026-06-16
Active, closed
Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
NCT07033585Type 2 Diabetes
DrugsFarxiga·Dapagliflozin
Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair
Phase 2/3
600
Maryland
2026-06-15
Not yet open
Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies
NCT07240805Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB), PSP, Lewy Body Dementia (LBD)
BioSensics
Observational
60
Maryland, Massachusetts
2026-06-15
Recruiting
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
NCT07104032Relapsed/Refractory Primary Central Nervous System Lymphoma
DrugsTirabrutinib·Temozolomide·Rituximab
Ono Pharmaceutical Co., Ltd.
Phase 3
132
Arizona, California, Connecticut, District of Columbia, Florida, Maryland, Massachusetts, Minnesota
2026-06-12
Active, closed
A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
NCT07656727Obesity and Cardiovascular Risk
DrugBGE-102
BioAge Labs, Inc.
Phase 2
160
Arizona, Arkansas, Florida, Kentucky, Maryland, Missouri, Nevada, New York
2026-06-11
Recruiting
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
NCT07595549Obesity, Overweight and/or Obesity, Overweight
DrugBerobenatide
Pfizer
Phase 3
954
California, Florida, Illinois, Indiana, Kentucky, Maryland, Michigan, Nebraska
2026-06-10
Active, closed
A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
NCT07639021Obesity
DrugsNNC0662-0419·Semaglutide
Novo Nordisk A/S
Phase 2
233
Alabama, California, Florida, Illinois, Indiana, Kentucky, Maryland, Missouri
2026-06-09
Recruiting
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
NCT07504458Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
DrugsArsenic Trioxide·ATRA
Quetzal Therapeutics
Phase 3
150
Alabama, California, Georgia, Kentucky, Maryland, Michigan, New York, North Carolina
2026-06-08
Recruiting
An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
NCT07593391Phelan-McDermid Syndrome
DrugNNZ-2591
Neuren Pharmaceuticals Limited
Phase 3
180
Alabama, California, Maryland, Massachusetts, New York, Ohio, Texas
2026-06-08
Active, closed
Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9
NCT07678775Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
DrugRibitol
ML Bio Solutions, Inc.
Phase 3
107
Arkansas, California, Colorado, Florida, Iowa, Kansas, Maryland, Minnesota
2026-06-05
Recruiting
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
NCT07563881Focal Seizure, Epilepsy, Focal Epilepsy
DrugRAP-219
Rapport Therapeutics Inc.
Phase 3
333
California, Florida, Georgia, Idaho, Indiana, Maryland, New Jersey, New York
2026-06-05
Recruiting
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
NCT07645820Atopic Dermatitis
Castle Biosciences Incorporated
Observational
450
Arizona, Maryland, Michigan, Missouri, Nevada, New Hampshire, Texas, Virginia
2026-06-04
Recruiting
Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region
NCT07566286Chin Augmentation
Galderma R&D
Not applicable
100
Connecticut, Florida, Georgia, Maryland, Tennessee, Texas
2026-06-03
Recruiting
Antibiotic Device for Osteomyelitis of the Extremities Pivotal Trial - Genex With Gentamicin.
NCT07270380Osteomyelitis
Biocomposites Ltd
Not applicable
139
California, Indiana, Maryland, New Jersey
2026-06
By invitation
Shortwave Infrared Surgical Imaging Device Study
NCT07744425Cholecystitis, Cholecystitis, Chronic, Chronic Calculous Cholecystitis, Primary Hyperparathyroidism
Cision Vision, Inc.
Observational
50
California, Illinois, Maryland
2026-05-29
Recruiting
A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia
NCT07610278Hypercholesterolaemia
DrugsQCZ484·Inclisiran
Novartis Pharmaceuticals
Phase 2
120
Alabama, California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2026-05-29
Recruiting
Open-label Study of SKY-GJB2 in Pediatric Subjects With GJB2-mediated Hearing Loss
NCT07627971GJB2-mediated Hearing Loss, GJB2 Gene Mutation, DFNB1A
Skylark Bio Inc.
Phase 1/2
10
Maryland, Massachusetts, Oklahoma, Pennsylvania
2026-05-28
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Connecticut, Florida, Georgia, Indiana, Maryland, New Jersey, New York, Ohio
2026-05-27
Recruiting
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
NCT07614776Neovascular Age-related Macular Degeneration, nAMD
Amgen
Phase 3
304
California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland, Massachusetts
2026-05-27
Recruiting
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
NCT07429266Polycythemia Vera
Ono Pharmaceutical Co., Ltd.
Phase 3
250
Florida, Georgia, Maryland, Michigan, New York, Ohio
2026-05-25
Recruiting
Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes
NCT07599982Type 1 Diabetes (T1D), Type 2 Diabetes (T2D)
DreaMed Diabetes
Not applicable
102
Maryland, Michigan, New York, North Carolina, Texas, Utah
2026-05-25
Recruiting
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
NCT07621718Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsZoldonrasib·Leucovorin·Irinotecan·Adrucil
Revolution Medicines, Inc.
Phase 3
670
Arizona, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts, New Jersey
2026-05-22
Not yet open
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
NCT07400107Obesity, Overweight, Diabetes Mellitus, Type 2
DrugsNNC0487-0111·Semaglutide
Novo Nordisk A/S
Phase 3
1,000
Florida, Georgia, Idaho, Maryland, Michigan, Texas, Virginia
2026-05-20
Recruiting
Crownlands Observing Progression With Neurons Study
NCT07611396Alzheimer s Disease, Mild Cognitive Impairment (MCI)
Crownlands
Observational
160
Maryland
2026-05-19
Recruiting
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
NCT07278479Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Small Cell Lung Cancer (SCLC)
Molecular Partners AG
Phase 1/2
138
Florida, Georgia, Maryland, Nebraska, New Jersey, Ohio
2026-05-18
Recruiting
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
NCT07392892Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
DrugsPF-08634404·Nivolumab
Pfizer
Phase 2/3
840
California, Colorado, Florida, Illinois, Maryland, Nevada, New Jersey, New York
2026-05-14
Recruiting
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
NCT07486934Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy, Steinert Disease
DrugZeleciment basivarsen
Dyne Therapeutics
Phase 3
150
California, Florida, Georgia, Indiana, Maryland, Missouri, New York, North Carolina
2026-05-14
Recruiting
A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants
NCT07525544HIV Infections
DrugMidazolam
ViiV Healthcare
Phase 1
214
Maryland
2026-05-14
Recruiting
Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica
NCT07286214Polymyalgia Rheumatica
DrugSarilumab
Sanofi
Phase 4
300
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Missouri
2026-05-12
Recruiting
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
NCT07441694Myeloproliferative Neoplasms
Incyte Corporation
Phase 1
218
Alabama, California, Connecticut, Florida, Georgia, Maryland, Massachusetts, Missouri
2026-05-11
Active, closed
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity
NCT07575932Overweight, Obesity, Overweight and/or Obesity, Overweight or Obesity
DrugsPF-08653945·Berobenatide
Pfizer
Phase 2
940
Arizona, California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2026-05-11
Recruiting
An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.
NCT07543120Hypertension (HTN)
DrugQCZ484
Novartis Pharmaceuticals
Phase 2
323
California, Florida, Georgia, Illinois, Kansas, Maryland, Michigan, Missouri
2026-05-07
Recruiting
A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies
NCT07606066Type 2 Diabetes
AstraZeneca
Observational
2,150
Arizona, Arkansas, California, Florida, Georgia, Illinois, Kansas, Maryland
2026-05-06
Recruiting
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
NCT07509151Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
DrugSurovatamig
AstraZeneca
Phase 3
420
California, Colorado, Connecticut, Illinois, Kansas, Kentucky, Maryland, Massachusetts
2026-05-05
Recruiting
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
NCT07326566Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM)
DrugsTemodar·Temozolomide
Black Diamond Therapeutics, Inc.
Phase 2
162
Alabama, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia, Maryland
2026-05-05
Recruiting
Investigation of the Delve Detect Cerebrospinal Fluid (CSF) Metagenomic Next-generation Sequencing (mNGS) Test When Used for the Initial Diagnostic Workup of Patients With Suspected Central Nervous System (CNS) Infection
NCT07435649Central Nervous System Infection
Delve Bio, Inc.
Not applicable
400
California, Georgia, Maryland, Massachusetts, Tennessee
2026-05-01
Recruiting
A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity
NCT07566390Obesity, Overweight
Novo Nordisk A/S
Phase 1
48
California, Maryland
2026-05-01
Not yet open
WearME-Pro Phase II: Remote Use Usability and Longitudinal Validation Study (Patch Form Factor).
NCT07430605Chronic Obstructive Pulmonary Disease (COPD)
LASARRUS Clinic and Research Center
Not applicable
82
Maryland
2026-05-01
Recruiting
NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies
NCT07563829Metastatic Malignant Neoplasm
NextPoint Therapeutics, Inc.
Phase 1
81
California, Maryland, New York, Tennessee, Texas, Virginia
2026-05-01
Recruiting
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
NCT07553637Treatment-resistant Depression (TRD)
Alto Neuroscience
Phase 2
178
Alabama, Arizona, California, Florida, Georgia, Indiana, Maryland, Massachusetts
2026-05
Recruiting
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
NCT07573176Depressive Disorder, Major
DrugSeltorexant
Janssen Research & Development, LLC
Phase 3
600
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Nevada
2026-04-30
Recruiting
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
NCT07516132Neovascular Age-Related Macular Degeneration (nAMD)
DrugOtx-Tki
Ocular Therapeutix, Inc.
Phase 3
850
California, Connecticut, Florida, Maryland, South Carolina, Texas
2026-04-27
By invitation
Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
NCT07393373Hypochondroplasia
DrugInfigratinib
QED Therapeutics, a BridgeBio company
Phase 2
135
California, Colorado, District of Columbia, Maryland, Missouri, Ohio, Tennessee, Wisconsin
2026-04-23
Recruiting
52-week Open Label Safety-Tolerability Study
NCT07369154Schizophrenia
DrugLB-102
LB Pharmaceuticals Inc.
Phase 3
900
Arizona, Arkansas, California, Florida, Georgia, Illinois, Maryland, Missouri
2026-04-23
Recruiting
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
NCT07565428Negative Symptoms of Schizophrenia
DrugsAripiprazole·Risperidone·Olanzapine
Minerva Neurosciences
Phase 3
380
California, Florida, Georgia, Maryland, New Jersey, New York, Texas
2026-04-23
Recruiting
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
NCT07419295Bladder Cancer
DrugsVinflunine·Sacituzumab tirumotecan·Docetaxel·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
590
District of Columbia, Maryland, Massachusetts, Michigan, New Jersey, New York, North Carolina, Ohio
2026-04-23
Recruiting
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
NCT07342478CLL / SLL, CLL (Chronic Lymphocytic Leukemia), CLL, Refractory, CLL, Relapsed
DrugsRocbrutinib·Pirtobrutinib
Newave Pharmaceutical Inc
Phase 3
306
Illinois, Maryland, Nevada, Ohio, Pennsylvania, Washington
2026-04-23
Recruiting
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT07365995Metastatic Castration-resistant Prostate Cancer
DrugsBNT324·Prednisone/Prednisolone·Docetaxel
BioNTech SE
Phase 3
736
California, Colorado, Florida, Illinois, Maryland, New York, Ohio, Tennessee
2026-04-22
Recruiting
PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
NCT07611214Lupus Nephritis
DrugsLupkynis·Anifrolumab
Aurinia Pharmaceuticals Inc.
Phase 4
150
California, Colorado, Florida, Georgia, Louisiana, Maryland, Missouri, Nevada
2026-04-22
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
NCT07425522Diabetic Macular Edema
DrugFaricimab
Genentech, Inc.
Phase 1
93
Arizona, California, Florida, Maryland, Pennsylvania, Tennessee, Texas, Virginia
2026-04-21
Recruiting
Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)
NCT07486960Psoriatic Arthritis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 2
140
Arizona, California, Florida, Idaho, Maryland, Missouri, Nebraska, New York
2026-04-20
Recruiting
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
NCT07441876Achondroplasia
DrugVosoritide
BioMarin Pharmaceutical
Phase 2/3
160
California, Delaware, Illinois, Maryland, Ohio, Pennsylvania, Texas
2026-04-20
Recruiting
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
NCT06796504Relapsing Remitting Multiple Sclerosis
SetPoint Medical Corporation
Not applicable
60
California, Georgia, Maryland, Minnesota, Texas, Washington, West Virginia, Wisconsin
2026-04-17
Recruiting
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
NCT07287670Diffuse Cutaneous Systemic Sclerosis
Mediar Therapeutics
Phase 2
85
Arizona, California, Colorado, Florida, Kansas, Maryland, Massachusetts, Minnesota
2026-04-16
Active, closed
A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants
NCT07534592Healthy Participants
DrugsElecoglipron·Rosuvastatin·Atorvastatin
AstraZeneca
Phase 1
48
California, Maryland
2026-04-16
Recruiting
An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)
NCT07264959Indolent Systemic Mastocytosis
Blueprint Medicines Corporation
Observational
150
Colorado, Illinois, Maryland, Massachusetts, Michigan, Missouri, Utah
2026-04-15
Recruiting
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
NCT07227311Multiple Myeloma
DrugsBelantamab mafodotin·Velcade·Carfilzomib·Pomalidomide
GlaxoSmithKline
Phase 2
200
California, Connecticut, Florida, Georgia, Louisiana, Maryland, Missouri, New Mexico
2026-04-15
Recruiting
Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric Bypass
NCT07015424Weight Regain, Weight Loss
Boston Scientific Corporation
Not applicable
108
California, Florida, Illinois, Maryland, Minnesota, New York, Texas, West Virginia
2026-04-14
Recruiting
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
NCT07430306Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
245
Alabama, Arizona, California, Florida, Illinois, Indiana, Louisiana, Maryland
2026-04-13
Recruiting
Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
NCT07175441Advanced Unresectable Hepatocellular Carcinoma
DrugsSTRIDE (durvalumab·RBS2418·Tremelimumab
Riboscience, LLC.
Phase 2
220
Maryland, Tennessee, Texas
2026-04-10
Recruiting
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
NCT07297979Ewing Sarcoma
DrugXaluritamig
Amgen
Phase 1
50
California, Maryland, Massachusetts, Minnesota, New York, Pennsylvania, Texas
2026-04-08
Recruiting
Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix
NCT07543757Prostate Cancer Detection
Sequenom, Inc.
Observational
500
California, Idaho, Kentucky, Maryland, New York, South Carolina
2026-04-03
Recruiting
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
NCT07225270Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC
DrugsRina-S·Bevacizumab
Genmab
Phase 3
544
Florida, Maryland, Ohio
2026-04-03
Recruiting
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
NCT07428499Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE
ADARx Pharmaceuticals, Inc.
Phase 3
90
Arizona, Arkansas, California, Florida, Maryland, Michigan, Missouri, Nevada
2026-04-02
Recruiting
Steady Stride Fall Prevention Protocol vs Standard of Care
NCT07092176Fall Prevention, Falls
Steady Strides: Fall Prevention and Stroke Rehabilitation Medical Institute
Not applicable
102
Maryland
2026-04-01
Recruiting
A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice
NCT07556159Asthma
Sanofi
Observational
2,500
Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland, Montana
2026-04-01
Recruiting
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
NCT07459647Schizophrenia
DrugML-007C-MA
MapLight Therapeutics
Phase 2
500
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2026-03-31
Recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
NCT07511205Healthy Participants, Obesity
AstraZeneca
Phase 1
104
California, Maryland
2026-03-30
Recruiting
PS-002 for the Treatment of IgA Nephropathy in Adults
NCT07182227Immunoglobulin A (IgA) Nephropathy
Purespring Therapeutics Limited
Phase 1/2
32
Florida, Maryland
2026-03-30
Recruiting
A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
NCT07571746Primary Membranous Nephropathy
DrugSurovatamig
AstraZeneca
Phase 2
43
California, Iowa, Maryland, New York, Texas
2026-03-28
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
NCT07440225Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
DrugsTiespectus·Eylea·Aflibercept
EyeBiotech Ltd.
Phase 2/3
960
Arizona, Arkansas, California, Florida, Illinois, Indiana, Maryland, Michigan
2026-03-27
Active, closed
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
NCT07446998Obesity & Overweight, Mobility Disability, HOMA-IR
DrugSemaglutide (Wegovy)
Veru Inc.
Phase 2
239
Arizona, Florida, Louisiana, Maryland, Mississippi, New York, North Carolina, Texas
2026-03-26
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
NCT07293351Advanced Renal Cell Carcinoma (RCC)
DrugsCasdatifan·Pumitamig·Cabozantinib·Yervoy
Bristol-Myers Squibb
Phase 1/2
474
California, Connecticut, District of Columbia, Florida, Indiana, Iowa, Maryland, Michigan
2026-03-26
Recruiting
A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy
NCT07493265Narcolepsy
DrugE2086
Eisai Inc.
Phase 2
64
California, Florida, Georgia, Maryland, Michigan, North Carolina, South Carolina, Texas
2026-03-26
Recruiting
Transition to KPL-387 Monotherapy Dosing & Administration Study
NCT07288216Recurrent Pericarditis, Heart Diseases, Pericarditis
DrugKPL-387
Kiniksa Pharmaceuticals International, plc
Phase 2
120
Arizona, California, Florida, Illinois, Maryland, Massachusetts, Minnesota, Missouri
2026-03-25
Recruiting
Continuous Dual Aspiration Technique With Zoom System for Stroke
NCT07491952Ischemic Stroke, Acute Stroke
Imperative Care, Inc.
Observational
750
Alabama, California, Florida, Georgia, Louisiana, Maryland, Minnesota, New York
2026-03-24
Recruiting
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
NCT07355296Proteinuric Kidney Diseases
DrugApecotrep
Boehringer Ingelheim
Phase 2
132
Alabama, California, Colorado, Florida, Illinois, Maryland, Michigan, New York
2026-03-23
Recruiting
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
NCT07293260Cardiovascular Disease
DrugOlpasiran
Amgen
Phase 3
406
Connecticut, Florida, Kansas, Maryland, Pennsylvania, Texas
2026-03-23
Active, closed
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
NCT07496450Influenza
ModernaTX, Inc.
Phase 3
4,050
California, Georgia, Idaho, Maryland, Nebraska, Ohio, Rhode Island, South Carolina
2026-03-23
By invitation
Evaluation of the Safety and Performance of a Bioresorbable Nasal Dressing Containing Mometasone Furoate (MF)
NCT07286201Chronic Rhinosinusitis (CRS), Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Polyganics BV
Not applicable
110
Colorado, Georgia, Illinois, Louisiana, Maryland, South Carolina, Texas, Utah
2026-03-19
Active, closed
Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms
NCT05987956ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Medicine Invention Design, Inc
Phase 2/3
600
Florida, Maryland
2026-03-18
Recruiting
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
NCT07473778HIV Infections
DrugsF/TAF·Emtricitabine/tenofovir disoproxil fumarate·Descovy·F/TDF
Gilead Sciences
Observational
3,000
Alabama, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2026-03-17
Recruiting
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
NCT07412470Kidney Transplant Rejection
DrugsRabbit anti-thymocyte globulin·Frexalimab·Mycophenolate Mofetil·Tacrolimus
Sanofi
Phase 2/3
526
Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan, New York, Ohio
2026-03-13
Recruiting
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
NCT07421700Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma
DrugsPF-08634404·Enfortumab Vedotin
Pfizer
Phase 1/2
132
Arkansas, California, Colorado, Connecticut, District of Columbia, Georgia, Illinois, Maryland
2026-03-11
Recruiting
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
NCT07286058Psoriatic Arthritis
DrugZasocitinib
Takeda
Phase 3
1,182
Arizona, California, Colorado, Florida, Maryland, Ohio, Tennessee, Texas
2026-03-11
Recruiting
Anastomotic Safety and Surveillance Using Real-time Enhanced Sensing Using xBar
NCT07337590Colorectal Cancer
Exero Medical Ltd.
Not applicable
80
Kentucky, Maryland, Nebraska, New York, Pennsylvania
2026-03-10
Active, closed
A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure
NCT07562087Lyme Disease
Tarsus Pharmaceuticals, Inc.
Phase 2
722
Maryland, Massachusetts, Minnesota, New Jersey, New York, Pennsylvania, Rhode Island
2026-03-09
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsCetuximab·Nab-paclitaxel·Gemcitabine
Revolution Medicines, Inc.
Phase 3
900
Arizona, California, Florida, Maryland, Massachusetts, Michigan, Minnesota, Nevada
2026-03-09
Active, closed
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
NCT07441252Overweight or Obesity and Elevated Liver Fat
DrugMaridebart cafraglutide
Amgen
Phase 2
180
Arizona, California, Florida, Louisiana, Maryland, Missouri, Nevada, Texas
2026-03-05
Active, closed
Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
NCT07458269Obesity
DrugRibupatide
Kailera
Phase 2
264
Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2026-03-04
Recruiting
GORE® TAG® Thoracic Branch Endoprosthesis Zone 0/1 Post-Approval Study
NCT07166133Aortic Arch Dissection, Aortic Arch Aneurysm
W.L.Gore & Associates
Not applicable
125
Arizona, California, Connecticut, District of Columbia, Florida, Maryland, North Carolina, Pennsylvania
2026-03-02
Active, closed
A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
NCT07427797Moderate to Severe Glabellar Lines
DrugCorabotase
Ipsen
Phase 3
309
Alabama, Arizona, California, Florida, Maryland, South Carolina, Texas, Virginia
2026-02-27
Recruiting
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)
NCT07325526Liver Cirrhosis
Boehringer Ingelheim
Phase 2
30
Arizona, California, Colorado, Florida, Georgia, Iowa, Kansas, Maryland
2026-02-27
By invitation
Persona SoluTion PPS Femur PMCF
NCT07286513Rhematoid Arthritis, Osteo Arthritis of the Knee, Traumatic Arthritis of Knee (Diagnosis), Polyarthritis
Zimmer Biomet
Observational
200
Colorado, Kentucky, Maryland
2026-02-26
Recruiting
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
NCT07404865Primary Sjogren's Disease
DrugTelitacicept
Vor Biopharma
Phase 3
250
Arizona, California, Colorado, Florida, Idaho, Illinois, Louisiana, Maryland
2026-02-26
Active, closed
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
NCT07400653Obesity, Overweight and/or Obesity, Overweight, Diabetes, Type 2
DrugBerobenatide
Pfizer
Phase 3
1,078
California, Colorado, Florida, Georgia, Maryland, Missouri, Nebraska, New Jersey
2026-02-24
Recruiting
Paclitaxel-Coated Pulmonary Balloon for the Treatment of Benign Central Airway Stenosis
NCT07191860Adult Subjects With Symptomatic Benign Airway Obstruction, Adult Benign Central Airway Stenosis, Adult Tracheobronchial Stenosis, Tracheal Stenosis
Airiver Medical, Inc.
Not applicable
200
Maryland
2026-02-24
Recruiting
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
NCT07484217Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
DrugSolriamfetol
Axsome Therapeutics, Inc.
Phase 3
508
Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Nevada
2026-02-23
Recruiting
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
NCT07449702Plaque Psoriasis
DrugORKA-001
Oruka Therapeutics, Inc.
Phase 2
240
Arizona, California, Connecticut, Florida, Illinois, Kentucky, Maryland, Massachusetts
2026-02-23
Recruiting
Ambulatory Long Length URodynamics Evaluation
NCT07425015Urology, Urinary Bladder, Overactive, Benign Prostatic Hyperplasia, Urodynamics
Bright Uro
Not applicable
101
Louisiana, Maryland, Missouri, Ohio, South Carolina, South Dakota, Texas, Washington
2026-02-17
Recruiting
A Study of Brenipatide in Participants With Opioid Use Disorder
NCT07420283Opioid Use Disorder
DrugsBuprenorphine·Brenipatide
Eli Lilly and Company
Phase 2
465
Arizona, Arkansas, California, Florida, Illinois, Indiana, Kentucky, Maryland
2026-02-13
Recruiting
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
NCT07210723Symptomatic Genetic Dilated Cardiomyopathy
DrugDanicamtiv
Kardigan, Inc.
Phase 2/3
332
Alabama, California, District of Columbia, Florida, Illinois, Louisiana, Maryland, Massachusetts
2026-02-13
Recruiting
Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy
NCT07215273Invasive Mould Infection
DrugVoriconazole
Elion Therapeutics, Inc.
Phase 2
60
Alabama, California, Georgia, Maryland, Massachusetts, Michigan, Missouri, Texas
2026-02-13
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT07369011Sleep Apnea, Obstructive, Obesity, Overweight
DrugEloralintide
Eli Lilly and Company
Phase 3
800
Alabama, California, Colorado, Florida, Georgia, Louisiana, Maryland, Michigan
2026-02-10
Recruiting
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
NCT07215702Sepsis, Acute Kidney Injury
DrugAZD4144
AstraZeneca
Phase 2
124
Arizona, California, Kansas, Maryland, Massachusetts, Michigan, New York, North Carolina
2026-02-10
Recruiting
A Study of Brenipatide in Adult Participants With Schizophrenia
NCT07410507Schizophrenia
DrugBrenipatide
Eli Lilly and Company
Phase 2
450
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts
2026-02-10
Active, closed
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination
NCT07425392Pneumococcal Vaccines
Drugs31-valent pneumococcal conjugate vaccine·Prevnar 20
Vaxcyte, Inc.
Phase 3
752
Arizona, Connecticut, Florida, Georgia, Indiana, Kansas, Louisiana, Maryland
2026-02-09
Recruiting
A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV
NCT07392372HIV -1 Infection
BioNTech SE
Phase 1
67
Illinois, Maryland, Missouri, New York
2026-02-09
Recruiting
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
NCT07412756Depressive Disorder, Major
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,000
California, Connecticut, Florida, Georgia, Indiana, Iowa, Maryland, Massachusetts
2026-02-09
Recruiting
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
NCT07280013Multiple Myeloma (MM)
DrugsCemsidomide·Elranatamab
C4 Therapeutics, Inc.
Phase 1
60
Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2026-02-06
Recruiting
A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
NCT07340320Type II Diabetes Mellitus
DrugCX11
Corxel Pharmaceuticals
Phase 2
240
Alabama, California, Florida, Georgia, Illinois, Indiana, Maryland, Massachusetts
2026-02-06
Active, closed
A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults
NCT07395024Healthy Volunteer
DrugsSetidegrasib·Carbamazepine·Fluconazole·Itraconazole
Astellas Pharma Global Development, Inc.
Phase 1
54
Maryland
2026-02-03
Recruiting
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
NCT07223203Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN
DrugsNucresiran·Vutrisiran
Alnylam Pharmaceuticals
Phase 3
125
Colorado, Illinois, Maryland, Massachusetts, Minnesota, New York, North Carolina, Tennessee
2026-02-03
Recruiting
Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty
NCT07214311Prosthetic-joint Infection
Peptilogics
Phase 2/3
240
Florida, Louisiana, Maryland, Massachusetts, New York, North Carolina, Ohio, Pennsylvania
2026-02-03
Recruiting
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
NCT07224360Sickle Cell Disease
CSL Behring
Phase 2
63
Arkansas, California, Florida, Georgia, Maryland, Mississippi, New York, Ohio
2026-02-02
Not yet open
Efficacy and Safety of Functional Neurogenesis Stimulation Therapy in Children With Autism Spectrum Disorder (ASD)
NCT07276555Autism Spectrum Disorder
Neurocytonix, Inc.
Not applicable
256
Maryland
2026-02-01
Recruiting
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
NCT07322003Amyotrophic Lateral Sclerosis
DrugPridopidine
Prilenia
Phase 3
500
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Maryland
2026-02-01
Recruiting
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
NCT07154823Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL)
Tempus AI
Observational
550
Iowa, Maryland, Missouri, Nevada, North Carolina, Ohio, Pennsylvania, South Dakota
2026-01-27
Recruiting
Neoadjuvant Darovasertib in Primary Uveal Melanoma
NCT07015190Uveal Melanoma
DrugDarovasertib
IDEAYA Biosciences
Phase 3
520
Arizona, California, Colorado, Florida, Maryland, Massachusetts, Michigan, Minnesota
2026-01-25
Recruiting
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
NCT07184619Treatment-resistant Schizophrenia
Newron Pharmaceuticals SPA
Phase 3
400
California, Florida, Georgia, Maryland, New York
2026-01-23
Recruiting
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT07096778Multiple Myeloma Refractory, Multiple Myeloma in Relapse
DrugsPomalidomide·Dexamethasone
CellCentric Ltd.
Phase 2
100
Arizona, California, Florida, Georgia, Illinois, Iowa, Maryland, Massachusetts
2026-01-22
Recruiting
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
NCT07332091Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
CSL Behring
Phase 2
84
Arizona, California, Florida, Indiana, Louisiana, Maryland, Michigan, Minnesota
2026-01-22
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT07216703Cervical Cancer
DrugsMvasi·Sacituzumab tirumotecan·Paraplatin·Avastin
Merck Sharp & Dohme LLC
Phase 3
1,023
Alabama, California, Florida, Georgia, Louisiana, Maryland, Minnesota, Nevada
2026-01-19
Recruiting
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
NCT06980480Multiple Myeloma, Secondary Immunodeficiency
Takeda
Phase 3
183
Alabama, California, Kansas, Maryland, Michigan, Missouri, New York
2026-01-14
Recruiting
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
NCT07325292Multiple Sclerosis
DrugsMRI contrast-enhancing preparations·Frexalimab
Sanofi
Phase 3
160
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland
2026-01-14
Recruiting
A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
NCT07300267Pneumococcal Infection
DrugPrevnar 20
Merck Sharp & Dohme LLC
Phase 1
210
California, Florida, Kansas, Kentucky, Maryland, Missouri, New York, South Carolina
2026-01-13
Recruiting
A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)
NCT07290062Amyotrophic Lateral Sclerosis
Insmed Gene Therapy LLC
Phase 1
23
California, Maryland, Massachusetts, Missouri, Ohio, Pennsylvania
2026-01-09
Recruiting
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
NCT07227454Depressive Disorder, Major
DrugsEsketamine·Midazolam
Janssen Research & Development, LLC
Phase 3
258
Alabama, District of Columbia, Georgia, Illinois, Maryland, Massachusetts, Minnesota, Ohio
2026-01-08
Recruiting
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
NCT07253285Overweight, Obesity
DrugsCagrilintide·Semaglutide
Novo Nordisk A/S
Phase 3
460
California, Florida, Georgia, Idaho, Indiana, Kansas, Louisiana, Maryland
2026-01-08
Active, closed
Study of VYD2311 for the Prevention of COVID-19
NCT07298434COVID-19
Invivyd, Inc.
Phase 3
1,770
California, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan
2026-01-08
Recruiting
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
NCT07349537Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC)
DrugCetuximab
Revolution Medicines, Inc.
Phase 1
574
Connecticut, Maryland, Massachusetts, Michigan, New York, Texas, Virginia
2026-01-08
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Arizona, Arkansas, California, Florida, Illinois, Indiana, Louisiana, Maryland
2026-01-06
Recruiting
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
NCT07115329Major Depressive Disorder
DrugZelquistinel
Syndeio Biosciences, Inc
Phase 2
164
Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland, Massachusetts
2026-01-05
Not yet open
Feasibility Study for VCool™ Intranasal Cooling System in Healthy Volunteers
NCT07361588Targeted Temperature Management
NeuroIntact Inc.
Not applicable
10
Maryland
2026-01
Active, closed
Clinical Utility of an Amniotic Membrane Allograft for Diabetic Foot Ulcer Wound Management
NCT06420245Diabetic Foot Ulcer
Legacy Medical Consultants
Not applicable
240
California, Connecticut, Florida, Illinois, Maryland, Oregon
2025-12-30
Recruiting
An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania
NCT07288320Bipolar I Disorder, Mania
DrugNBI-1117568
Neurocrine Biosciences
Phase 2
150
Arkansas, California, Florida, Georgia, Maryland, New Jersey, New York, Texas
2025-12-24
Recruiting
A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta
NCT07078383Aortic Aneurysm, Aortic Aneurysm and Dissection, Aortic Diseases, Aneurysm of Aorta, Thoracic
Vascutek Ltd.
Not applicable
150
California, Colorado, District of Columbia, Florida, Illinois, Maryland, Massachusetts, Missouri
2025-12-19
Active, closed
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
NCT07311850Obesity and Overweight
DrugBerobenatide
Pfizer
Phase 3
3,578
Arizona, California, Colorado, Florida, Georgia, Maryland, Missouri, Nebraska
2025-12-19
Recruiting
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
NCT07287982Spinal Muscular Atrophy (SMA)
DrugARGX-119
argenx
Phase 2
60
Arkansas, California, Connecticut, Florida, Illinois, Iowa, Maryland, Massachusetts
2025-12-19
Recruiting
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
NCT07315113EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients
DrugsNXP900·Osimertinib
Nuvectis Pharma, Inc.
Phase 1
18
Maryland, Massachusetts, Oregon, Pennsylvania, Texas, Virginia
2025-12-18
Recruiting
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
NCT07246590Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Verrica Pharmaceuticals Inc.
Phase 3
300
Florida, Indiana, Maryland, Tennessee, Texas
2025-12-17
Active, closed
Study to Evaluate Xtresse Serum in Individuals With Thinning Hair
NCT07228156Thin Hair, Hair Loss, Alopecia, Thinning Hair
Restore Biologics Holdings, Inc. dba Xtressé
Not applicable
40
Florida, Maryland, Washington
2025-12-17
Recruiting
A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
NCT07091019Chronic Myelogenous Leukemia - Chronic Phase
Novartis Pharmaceuticals
Observational
1,000
Alabama, California, Connecticut, Florida, Illinois, Maryland, Missouri, New York
2025-12-17
Recruiting
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
NCT07300969Major Depressive Disorder (MDD)
DrugDT-101
Draig Therapeutics Ltd
Phase 2
300
Arkansas, California, Florida, Georgia, Maryland, Massachusetts, Mississippi, Nevada
2025-12-16
Recruiting
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07288138Metabolic Dysfunction-associated Steatohepatitis
DrugECC4703
Eccogene
Phase 2
160
Arizona, Arkansas, California, Florida, Georgia, Indiana, Louisiana, Maryland
2025-12-15
Recruiting
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
NCT07276581Rheumatoid Arthritis
AstraZeneca
Phase 2
320
Arizona, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2025-12-15
Recruiting
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
NCT07226349Advanced Solid Tumor
DrugsBGB-43395·Fulvestrant
BeOne Medicines
Phase 1
105
Alabama, California, Connecticut, Maryland, Massachusetts, Texas, Wisconsin
2025-12-11
Recruiting
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
NCT07144163Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 3
150
California, Colorado, Florida, Georgia, Illinois, Maryland, Michigan, Minnesota
2025-12-11
Active, closed
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
NCT07219602Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)
DrugsEzetimibe FDC·Obicetrapib
NewAmsterdam Pharma
Phase 3
300
Arizona, California, Florida, Idaho, Illinois, Kentucky, Maine, Maryland
2025-12-11
Recruiting
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants
NCT07290283Healthy Participants
AstraZeneca
Phase 1
176
California, Maryland
2025-12-10
Recruiting
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
NCT07195591Glioblastoma
DrugTemozolomide
GT Medical Technologies, Inc.
Phase 3
766
Arizona, California, Florida, Georgia, Maryland, New Hampshire, New Jersey, New York
2025-12-10
Recruiting
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
NCT07107945Chronic Kidney Disease
DrugDapagliflozin
Boehringer Ingelheim
Phase 3
120
Alabama, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2025-12-09
Recruiting
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
NCT07269210Severe Hypertriglyceridemia
Eli Lilly and Company
Phase 2
60
Arizona, California, Connecticut, Florida, Illinois, Indiana, Kentucky, Maryland
2025-12-08
Recruiting
Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults
NCT07249463Cryptosporidiosis
Novartis Pharmaceuticals
Phase 2
80
Maryland, Ohio
2025-12-08
Recruiting
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
NCT07311993Breast Cancer
DrugCLR 131
Cellectar Biosciences, Inc.
Phase 1
60
Florida, Maryland, Minnesota, New Jersey
2025-12-05
Recruiting
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
NCT07209111Neoplasm Malignant
DrugsCalderasib·Cetuximab
Merck Sharp & Dohme LLC
Phase 2
150
Maryland, Michigan, Nevada, New Jersey, Utah, Virginia
2025-12-04
Recruiting
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)
NCT06980948Chronic Neuropathic Pain
Sangamo Therapeutics
Phase 1/2
27
Arizona, Arkansas, California, Maryland, Massachusetts, New Hampshire, New York, North Carolina
2025-12-04
Active, closed
Healthy Volunteer Study
NCT07270783Healthy Volunteer
DrugD-2570
InventisBio Co., Ltd
Phase 1
36
Maryland
2025-12-04
Recruiting
A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age
NCT07222670Viral Respiratory Infection, Viral Respiratory Illnesses
ENA Respiratory Pty Ltd
Phase 2
1,100
Maryland, North Carolina
2025-12-04
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399Squamous Cell Carcinoma of Head and Neck
DrugsAmivantamab·Cisplatin·Carboplatin·Pembrolizumab
Janssen Research & Development, LLC
Phase 3
500
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Maryland
2025-12-03
Active, closed
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07290569Plaque Psoriasis
DrugORKA-001
Oruka Therapeutics, Inc.
Phase 2
160
Arizona, Arkansas, California, Florida, Illinois, Indiana, Maryland, New York
2025-12-03
Recruiting
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
NCT07276724Severe Asthma
DrugGB-0895
Generate Biomedicines
Phase 3
786
California, Colorado, Florida, Georgia, Illinois, Maryland, Michigan, Mississippi
2025-12-03
Recruiting
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229Alzheimer Disease, Agitation
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
650
Arizona, California, Florida, Georgia, Maryland, Massachusetts, Michigan, Minnesota
2025-12-02
Active, closed
A Study of DII235 in Adults With Elevated Lipoprotein(a)
NCT07235046Lipoprotein Disorder
Novartis Pharmaceuticals
Phase 2
234
Alabama, Arkansas, California, Florida, Georgia, Illinois, Louisiana, Maryland
2025-12-02
Recruiting
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
NCT07219940Healthy Subjects, Exosome, Targeted Therapy
Shine-On Biomedical Co., Ltd.
Phase 1
15
Maryland
2025-12-01
Recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146Small-cell Lung Cancer
DrugZL-1310
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
California, Colorado, Connecticut, Florida, Illinois, Iowa, Kentucky, Maryland
2025-11-30
Recruiting
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
NCT07227402Renal Cell Carcinoma
DrugsZanzalintinib·Belzutifan·Cabozantinib
Merck Sharp & Dohme LLC
Phase 3
904
Alaska, California, Maine, Maryland, Minnesota, Nebraska, North Carolina, Tennessee
2025-11-26
Recruiting
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
NCT07233239Focal Seizures
DrugCannabidiol
Jazz Pharmaceuticals
Phase 1
100
Arizona, California, Connecticut, Florida, Georgia, Illinois, Maryland, Michigan
2025-11-26
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
NCT07223047Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
DrugsCetuximab·Nab-paclitaxel·Gemcitabine·Pembrolizumab
Bristol-Myers Squibb
Phase 1/2
252
Maryland, Texas, Utah, Virginia
2025-11-25
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed
AstraZeneca
Phase 1/2
152
Arizona, California, Florida, Maryland, Michigan, Minnesota, Ohio, Rhode Island
2025-11-24
Recruiting
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
NCT07213778Symptomatic Venous Thromboembolism (VTE)
DrugsCenvacibart·Acetylsalicylic acid
Regeneron Pharmaceuticals
Phase 3
2,000
California, Colorado, Florida, Illinois, Indiana, Kansas, Maryland, Massachusetts
2025-11-24
Recruiting
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
NCT07286175Bipolar Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 2
400
California, Connecticut, Florida, Georgia, Iowa, Maryland, Massachusetts, Pennsylvania
2025-11-24
Recruiting
Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
NCT07209462Fragile X Syndrome
DrugMRM-3379
Mirum Pharmaceuticals, Inc.
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts
2025-11-22
Recruiting
Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants
NCT06971939Macular Telangiectasia Type 2 (MacTel)
Neurotech Pharmaceuticals
Phase 4
234
California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-11-21
Recruiting
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
NCT07205718Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2
223
California, Connecticut, Florida, Maryland, Michigan, Missouri, Ohio, Oregon
2025-11-19
Recruiting
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
NCT07169279Achondroplasia
QED Therapeutics, a BridgeBio company
Phase 2
77
California, Maryland, Wisconsin
2025-11-19
Recruiting
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
NCT07235085Non-Proliferative Diabetic Retinopathy
Ocular Therapeutix, Inc.
Phase 3
930
Maryland
2025-11-17
Active, closed
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
NCT07232719Obesity, Overweight
DrugRetatrutide
Eli Lilly and Company
Phase 3
250
California, Florida, Illinois, Kentucky, Louisiana, Maryland, Missouri, New Jersey
2025-11-17
Recruiting
A Multicenter, Prospective Blood Collection Study in a Kidney Transplant Population
NCT07006831Kidney Disease, Kidney Transplant, Transplant Recipient, Renal Function
Devyser Inc.
Observational
400
California, Georgia, Maryland, Massachusetts, Utah
2025-11-14
Active, closed
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
NCT07074886Multiple Sclerosis
Hoffmann-La Roche
Phase 2
193
California, Colorado, Florida, Maryland, Massachusetts, New York, Tennessee, Washington
2025-11-13
Recruiting
A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
NCT07281079Phelan-McDermid Syndrome
DrugNNZ-2591
Neuren Pharmaceuticals Limited
Phase 3
160
Alabama, California, District of Columbia, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-11-12
Recruiting
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
NCT06157151Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, Recurrent Cervical Carcinoma
DrugPembrolizumab
Precigen, Inc
Phase 2
24
Arkansas, Maryland, Washington
2025-11-11
Active, closed
Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT07220577Atopic Dermatitis
DrugGIA632
Novartis Pharmaceuticals
Phase 2
34
California, Maryland, New Jersey
2025-11-10
Recruiting
Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease
NCT07228364Autosomal Dominant Polycystic Kidney Disease
DrugAZD1613
AstraZeneca
Phase 1
40
Alabama, California, Florida, Kansas, Maryland, Minnesota, Texas
2025-11-10
Recruiting
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration
ADARx Pharmaceuticals, Inc.
Phase 2
240
Arizona, California, Florida, Maryland, Nevada, Pennsylvania, Texas, Utah
2025-11-10
Active, closed
A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)
NCT07300085Healthy Participants
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1
710
California, Maryland
2025-11-08
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
DrugsObrixtamig·Etoposide·Atezolizumab·Carboplatin
Boehringer Ingelheim
Phase 3
670
Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Maryland, Michigan
2025-11-07
Recruiting
Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA
NCT07089576Aortic Arch Aneurysm, Aortic Arch Dissection, Chronic Aortic Dissection, Acute Aortic Dissection
Artivion Inc.
Not applicable
132
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Maryland
2025-11-04
Recruiting
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
NCT07108283Nonsegmental Vitiligo
DrugZasocitinib
Takeda
Phase 2
200
Arkansas, California, Florida, Louisiana, Maryland, Michigan, New York, Ohio
2025-11-03
Recruiting
Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.
NCT07216742Infertility (IVF Patients)
Granata Bio Corporation
Phase 3
659
California, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Maryland
2025-11-01
Recruiting
A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC
NCT06699121Primary Sclerosing Cholangitis (PSC)
LISCure Biosciences
Phase 2
87
California, Colorado, Iowa, Maryland, Minnesota, Tennessee, Washington
2025-11
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593Peripheral Arterial Disease
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,205
Alabama, Arizona, California, Colorado, Florida, Indiana, Maryland, Michigan
2025-10-31
Recruiting
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
NCT07201051Bronchiectasis
DrugGSK3862995B
GlaxoSmithKline
Phase 2
363
Alabama, Arizona, California, Colorado, Florida, Indiana, Louisiana, Maryland
2025-10-30
Recruiting
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT07173751Breast Neoplasms
DrugsEribulin·Pumitamig·Gemcitabine·Carboplatin
BioNTech SE
Phase 3
558
Arkansas, California, Florida, Illinois, Kentucky, Maine, Maryland, Massachusetts
2025-10-30
Recruiting
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
NCT07332000Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
DrugsAglatimagene besadenovec·Valacyclovir
Candel Therapeutics, Inc.
Phase 2
45
Arizona, Colorado, Maryland, Nevada, New Jersey, South Carolina
2025-10-30
Recruiting
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
NCT07219615Chronic Spontaneous Urticaria
DrugsLitfulo·Ritlecitinib
Pfizer
Phase 2
200
Arizona, Arkansas, California, Colorado, Illinois, Maryland, Michigan, Oklahoma
2025-10-30
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
DrugAvacincaptad Pegol
ONL Therapeutics
Phase 2
324
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland
2025-10-28
By invitation
Clinical Trial of Vormatrigine in Adult Patients With Epilepsy
NCT07287163Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure
Praxis Precision Medicines
Phase 3
700
Florida, Louisiana, Maryland, Michigan, Missouri, New Jersey, New York, Pennsylvania
2025-10-27
Recruiting
BoxX-NoAF Clinical Trial
NCT06989775Post Operative Atrial Fibrillation, Atrial Fibrillation, Postoperative
AtriCure, Inc.
Not applicable
960
Arkansas, California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan
2025-10-24
Recruiting
A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars
NCT07207369Acne Scars
AbbVie
Phase 3
395
Arizona, California, Connecticut, Georgia, Maryland, New York, North Carolina, Texas
2025-10-24
Recruiting
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT07213791Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms
Eli Lilly and Company
Phase 1
241
California, Florida, Indiana, Maryland, Massachusetts, Michigan, Minnesota, Missouri
2025-10-22
Active, closed
Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)
NCT07074977Chronic Pruritus of Unknown Origin
DrugNemolizumab
Galderma R&D
Phase 2
50
Alabama, Arizona, California, Florida, Indiana, Kentucky, Maryland, Michigan
2025-10-20
Recruiting
Virtue® SAB in the Treatment of Coronary ISR Trial
NCT07045194Coronary Artery Disease
Orchestra BioMed, Inc
Not applicable
740
Florida, Indiana, Kansas, Maryland, Michigan, New York, North Carolina, Ohio
2025-10-20
Recruiting
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
NCT07175428Atrial Fibrillation (AF)
DrugsAmrecibart·Cenvacibart·Apixaban
Regeneron Pharmaceuticals
Phase 2
1,200
Alabama, California, Florida, Georgia, Indiana, Louisiana, Maryland, Massachusetts
2025-10-20
Recruiting
ARC-IM System to Manage Symptomatic Blood Pressure Instability Secondary to Chronic Spinal Cord Injury
NCT07147296Spinal Cord Injuries, Blood Pressure Disorders
ONWARD Medical, Inc.
Not applicable
60
Arkansas, Colorado, Florida, Georgia, Kentucky, Maryland, Massachusetts, Minnesota
2025-10-17
Recruiting
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
NCT07143669Clonal Mast Cell Disease, KIT D816V Mutation, Suspected KITD816V Mutated Clonal Mast Cell Disease
Blueprint Medicines Corporation
Observational
750
Alabama, California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2025-10-17
Recruiting
A Study of Brenipatide in Participants With Alcohol Use Disorder
NCT07219953Alcohol Use Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,100
Arizona, Arkansas, California, Florida, Illinois, Maryland, Massachusetts, New York
2025-10-16
Recruiting
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
NCT07219966Alcohol Use Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,100
Alabama, Arizona, Arkansas, California, Colorado, Florida, Illinois, Maryland
2025-10-15
Recruiting
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
NCT07221500Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
DrugBexobrutideg
Nurix Therapeutics, Inc.
Phase 2
100
Arizona, California, Colorado, Florida, Indiana, Iowa, Maryland, Michigan
2025-10-15
Recruiting
Long-Term Stability of the Glide Control Strategy
NCT07222085Upper Limb Amputation Above Elbow, Upper Limb Amputation Below Elbow
Infinite Biomedical Technologies
Not applicable
12
Maryland, Massachusetts, North Carolina, South Carolina, Virginia
2025-10-15
Active, closed
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
NCT07157254Angelman Syndrome
DrugApazunersen
Ultragenyx Pharmaceutical Inc
Phase 2
60
California, Illinois, Maryland, Missouri, North Carolina, Ohio, Texas
2025-10-13
Recruiting
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women
NCT07224399Healhty, Overweight or Obesity
DrugBGM1812
BrightGene Bio-Medical Technology Co., Ltd.
Phase 1
60
Maryland
2025-10-09
Recruiting
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07215234Geographic Atrophy
Sanofi
Phase 1/2
104
Arizona, California, Florida, Georgia, Illinois, Maryland, Nevada, North Carolina
2025-10-09
Recruiting
A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)
NCT06655883Insomnia
Merck Sharp & Dohme LLC
Phase 3
300
California, Connecticut, Florida, Georgia, Maryland, New Jersey, Oklahoma, Pennsylvania
2025-10-09
Recruiting
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
NCT07175285Systemic Lupus Erythematosus (SLE)
Bristol-Myers Squibb
Observational
223
California, Florida, Georgia, Illinois, Maryland, Michigan, Montana, New Jersey
2025-10-08
Recruiting
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
NCT07100106Breast Cancer
DrugsRGT-419B·Giredestrant·Abemaciclib
Genentech, Inc.
Phase 1/2
285
Arizona, California, Florida, Georgia, Illinois, Maine, Maryland, Massachusetts
2025-10-07
Recruiting
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
NCT07023614Non-obstructive Hypertrophic Cardiomyopathy
Imbria Pharmaceuticals, Inc.
Phase 2
165
California, District of Columbia, Florida, Illinois, Maryland, Massachusetts, Michigan, Minnesota
2025-10-06
Recruiting
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
NCT07008118Myeloproliferative Neoplasms
Incyte Corporation
Phase 1
120
Arizona, California, Colorado, Florida, Illinois, Maryland, New York, North Carolina
2025-10-01
Not yet open
Safety and Tolerability of StroMel™ in Subjects with Moderate to Severe Osteoarthritis of the Knee Joint
NCT04750252Osteo Arthritis Knee
Akan Biosciences, LLC
Phase 1/2
20
Maryland
2025-10-01
By invitation
A Long-Term Study of Navenibart in Participants With Hereditary Angioedema
NCT07204938Hereditary Angioedema (HAE)
DrugNavenibart
Astria Therapeutics, Inc.
Phase 3
145
Arizona, Arkansas, California, Colorado, Maryland, Ohio, Pennsylvania
2025-10-01
Recruiting
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis
NCT07221240Amyotrophic Lateral Sclerosis
PRG Science & Technology Co., Ltd.
Phase 1
48
Maryland
2025-10-01
Recruiting
Study of COYA 302 for the Treatment of ALS
NCT07161999Amyotrophic Lateral Sclerosis (ALS)
Coya Therapeutics
Phase 2/3
120
Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-10-01
Recruiting
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
NCT07181161Metastatic Prostate Cancer
DrugPalacaparib
AstraZeneca
Phase 1/2
283
Arkansas, California, Maryland, Massachusetts, Michigan, New York, Rhode Island, South Carolina
2025-10-01
Recruiting
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
NCT07106762Urothelial Cancer
DrugsIza-bren·Gemcitabine·Cisplatin·Carboplatin
Bristol-Myers Squibb
Phase 2/3
470
Arizona, California, Colorado, District of Columbia, Florida, Kentucky, Maryland, Massachusetts
2025-09-30
Recruiting
Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)
NCT07195656Overactive Bladder (OAB)
FemPulse Corporation
Not applicable
151
California, Florida, Illinois, Kentucky, Maryland, Minnesota, Nebraska, North Carolina
2025-09-30
Active, closed
Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder
NCT07220460Bipolar I or II Disorder
DrugABBV-932
AbbVie
Phase 2
84
Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana, Maryland
2025-09-30
By invitation
Pilot Study to Evaluate the Efficacy and Safety of Xvie Delivered Into the Scalp by Microneedling in Women With Self-perceived Thinning Hair
NCT07221773Hair Thinning
Restore Biologics Holdings, Inc. dba Xtressé
Not applicable
15
Florida, Maryland
2025-09-29
Recruiting
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
NCT07133633Radiographic Axial Spondyloarthritis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 2
315
Arizona, California, Florida, Illinois, Maryland, Missouri, Montana, Nebraska
2025-09-26
Recruiting
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
NCT07129993Urothelial Cancer, Bladder Cancer
DrugsDato-DXd·Gemcitabine·Cisplatin·Carboplatin
Daiichi Sankyo
Phase 2/3
630
California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-09-26
Recruiting
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
NCT07102381HER2-positive Breast Cancer, Breast Cancer
DrugsZanidatamab·Pertuzumab·Trastuzumab·Docetaxel
Jazz Pharmaceuticals
Phase 2
125
California, Colorado, Florida, Iowa, Louisiana, Maine, Maryland, Michigan
2025-09-24
Recruiting
Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
NCT07101094Schizophrenia
Bristol-Myers Squibb
Observational
300
California, Florida, Illinois, Maryland, Massachusetts, Nebraska, New Jersey, New York
2025-09-22
Recruiting
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
NCT07053423Chronic Obstructive Pulmonary Disease
DrugDupilumab
Sanofi
Phase 4
218
Alabama, Florida, Georgia, Kansas, Maryland, Massachusetts, North Carolina, Pennsylvania
2025-09-22
Active, closed
Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder
NCT07221578Social Anxiety Disorder (SAD)
Vanda Pharmaceuticals
Phase 3
500
Arizona, California, Colorado, Florida, Georgia, Louisiana, Maryland, Missouri
2025-09-22
Recruiting
Use of fenoTRACK Device for Monitoring Changes of Fractional Exhaled Nitric Oxide (FeNO) in Uncontrolled Asthma Subjects and Controlled Asthma Subjects
NCT07228026Asthma
Biometry Inc
Observational
160
California, Florida, Georgia, Maine, Maryland, Nebraska, North Carolina, Ohio
2025-09-17
Recruiting
Bladder EpiCheck Product Development Study
NCT07514143Suspicion of Bladder Cancer, NMIBC Surveillance
Nucleix Ltd.
Observational
1,000
California, Maryland
2025-09-15
By invitation
5-Year Postoperative Outcomes of Patients Who Completed the CREST Study
NCT07480343Open-angle Glaucoma (OAG)
Iantrek, Inc.
Observational
250
California, Florida, Georgia, Maryland, Nevada, Pennsylvania, Tennessee, Utah
2025-09-15
Recruiting
Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)
NCT07094087Complex Cardiovascular Surgery With Cardiopulmonary Bypass
CSL Behring
Phase 3
200
California, Georgia, Illinois, Kansas, Maryland, New Jersey, New York, Ohio
2025-09-15
Active, closed
Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix
NCT07182838HIV Infections
DrugBCG Vaccine Mix for percutaneous use
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Phase EARLY_PHASE1
20
Maryland
2025-09-12
Recruiting
A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO
NCT07205887Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
DrugsRestoret·Aflibercept
EyeBiotech Ltd.
Phase 2
160
Arizona, California, Colorado, Florida, Illinois, Maryland, Mississippi, New Jersey
2025-09-12
Recruiting
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
NCT07029828Severe Alopecia Areata
DrugsRitlecitinib higher·Ritlecitinib lower
Pfizer
Phase 3
140
California, Florida, Indiana, Maryland, Michigan, Nebraska, New Mexico, New York
2025-09-10
Recruiting
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
NCT06726161Hepatocellular Carcinoma (HCC)
RayzeBio, Inc.
Phase 1/2
590
Alabama, Arizona, California, Florida, Kentucky, Maryland, Minnesota, Missouri
2025-09-05
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443Metastatic Castration-resistant Prostatic Neoplasms
DrugsJNJ-87189401·Pasritamig
Janssen Research & Development, LLC
Phase 3
1,203
California, Colorado, Connecticut, District of Columbia, Florida, Iowa, Louisiana, Maryland
2025-09-02
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
NCT07023289Colorectal Cancer
DrugTelisotuzumab Adizutecan
AbbVie
Phase 2
140
Alabama, California, Florida, Illinois, Maryland, Massachusetts, Michigan, Minnesota
2025-09-02
Recruiting
A Study to Assess How Effective and Safe NVD003 is for Treating Patients With Congenital Pseudarthrosis of the Tibia.
NCT07112443Congenital Pseudarthrosis of Tibia
Novadip Biosciences
Phase 3
12
Arizona, California, Maryland, Minnesota
2025-09-02
Recruiting
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
ADARx Pharmaceuticals, Inc.
Phase 3
90
Arizona, Arkansas, California, Colorado, Florida, Maryland, Michigan, Missouri
2025-08-28
Recruiting
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
NCT07191483Cognitive Impairment Associated With Schizophrenia (CIAS)
Kynexis B.V.
Phase 2
150
Arkansas, California, Florida, Georgia, Illinois, Maryland, Missouri, New Jersey
2025-08-27
Recruiting
Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare
NCT07145229Acute Gouty Arthritis, Gout Flare, Gout Flares, Acute Gout Flare
DrugsABP-745 A·ABP-745 B·Colchicine
Atom Therapeutics Co., Ltd
Phase 2
380
Arizona, California, Georgia, Illinois, Iowa, Louisiana, Maryland, Mississippi
2025-08-26
Recruiting
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
NCT06925321Invasive Mold Infections
DrugFosmanogepix
Basilea Pharmaceutica
Phase 3
234
Alabama, California, Florida, Illinois, Kentucky, Maryland, Michigan, Minnesota
2025-08-26
Recruiting
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
NCT07160244Healthy
DrugPrevnar 20
Pfizer
Phase 3
6,000
Alabama, Arizona, California, Colorado, Florida, Idaho, Louisiana, Maryland
2025-08-25
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
DrugsEmpasiprubart·IVIG
argenx
Phase 3
218
Alabama, California, Colorado, District of Columbia, Florida, Kentucky, Louisiana, Maryland
2025-08-22
Recruiting
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
NCT07020117Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer
Aktis Oncology, Inc.
Phase 1
150
California, Florida, Iowa, Kansas, Maryland, Michigan, New York, Pennsylvania
2025-08-22
Active, closed
A Study of SPY072 in Rheumatic Disease
NCT07148414Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases
DrugSPY072
Spyre Therapeutics, Inc.
Phase 2
285
Arizona, California, Florida, Illinois, Maryland, Pennsylvania, Texas
2025-08-21
Not yet open
A Phase 1 Study Evaluating the Safety, Tolerability, and Immunogenicity of V4020 Vaccine in Healthy Volunteers
NCT07088822Venezuelan Equine Encephalitis, Venezuelan Equine Encephalitis Virus Infection
Medigen, Inc.
Phase 1
39
Maryland
2025-08-15
Active, closed
Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms
NCT07145333SCLC
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Phase 2/3
600
Maryland
2025-08-12
Recruiting
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
NCT06975865Sickle Cell Disease
DrugRilzabrutinib
Sanofi
Phase 3
192
Alabama, Arizona, California, Florida, Illinois, Indiana, Louisiana, Maryland
2025-08-12
Recruiting
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects
NCT07166081Non-diabetic Overweight or Obese
DrugBGM0504
BrightGene Bio-Medical Technology Co., Ltd.
Phase 1
80
Maryland
2025-08-11
Recruiting
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
NCT06927739Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease
Abcentra
Phase 2
240
California, Florida, Indiana, Kentucky, Maryland, Michigan
2025-08-11
Recruiting
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
NCT07098338Non-Small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Dato-DXd
AstraZeneca
Phase 2
278
California, Georgia, Maryland, Texas, Virginia
2025-08-07
Recruiting
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
NCT06699849Sickle Cell Disease Vaso-occlusive Crisis
DrugIVIG
CSL Behring
Phase 2
70
California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan, Missouri
2025-08-07
Recruiting
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
NCT07007793Primary Hyperaldosteronism
DrugBaxdrostat
AstraZeneca
Phase 3
250
California, Connecticut, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Mississippi
2025-08-07
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803Prostate Cancer
DrugsPrednisolone/prednisone·Saruparib·Abiraterone
AstraZeneca
Phase 3
700
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Maryland
2025-08-06
Recruiting
FiberLocker® System Augmentation of Rotator Cuff Repairs
NCT06918041Rotator Cuff Tear, Rotator Cuff Tears, Rotator Cuff Tears of the Shoulder
ZuriMED Technologies Inc.
Not applicable
60
Illinois, Maryland, North Carolina, Oregon
2025-08-05
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965Breast Cancer
DrugsPrifetrastat·Exemestane·Everolimus·Fulvestrant
Pfizer
Phase 3
400
Arizona, California, Colorado, Connecticut, District of Columbia, Georgia, Illinois, Maryland
2025-08-05
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
NCT07145918Schizophrenia
DrugEmraclidine
AbbVie
Phase 2
268
Arkansas, California, Maryland, New Jersey, Texas
2025-08-04
Not yet open
Clinical Performance Study of Microbio InfectID-BSI for Detection of Bacteria and Yeast With Patient Blood Samples
NCT06531031Bloodstream Infection, Sepsis, Septic Shock
Microbio Co Ltd
Observational
1,500
Indiana, Maryland, New Mexico, Tennessee, Texas
2025-08
Active, closed
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
NCT07029711Severe Alopecia Areata
DrugsRitlecitinib higher·Ritlecitinib lower
Pfizer
Phase 3
208
California, Colorado, District of Columbia, Florida, Illinois, Indiana, Maryland, Michigan
2025-07-31
Recruiting
Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus
NCT07096193Chronic Hepatitis Delta
Gilead Sciences
Phase 1/2
200
California, Kentucky, Maryland, New York
2025-07-31
Recruiting
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
NCT07126262Hypochondroplasia
DrugVosoritide
BioMarin Pharmaceutical
Phase 2
60
Arizona, California, District of Columbia, Illinois, Maryland, Minnesota, Missouri, Texas
2025-07-30
Recruiting
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
NCT06990399Macular Edema Secondary to Inflammation
DrugKSI-101
Kodiak Sciences Inc
Phase 3
600
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland
2025-07-30
Recruiting
Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
NCT06850805Chronic Rhinosinusitis Without Nasal Polyps
Optinose US Inc.
Phase 3
84
Alabama, Arizona, California, Colorado, Georgia, Illinois, Kentucky, Maryland
2025-07-28
Active, closed
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder
NCT07046494Bipolar 1 Disorder
DrugRAP-219
Rapport Therapeutics Inc.
Phase 2
253
Arkansas, California, Florida, Georgia, Illinois, Maryland, Missouri, New York
2025-07-25
Not yet open
A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis
NCT06989567Sickle Cell Disease
DrugL-Citrulline
Asklepion Pharmaceuticals, LLC
Phase 3
120
District of Columbia, Florida, Georgia, Maryland, Michigan, North Carolina
2025-07-25
Active, closed
Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma
NCT07120503Asthma (Diagnosis)
DrugWIN378
Windward Bio
Phase 2
136
California, Florida, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska
2025-07-24
Recruiting
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT06757634Breast Cancer
DrugsGedatolisib·Ribociclib·Palbociclib·Letrozole
Celcuity Inc
Phase 3
1,180
California, Florida, Kansas, Kentucky, Maryland, Massachusetts, Michigan, Missouri
2025-07-24
Recruiting
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT07064759Neovascular Age-Related Macular Degeneration (nAMD)
DrugsEYLEA (aflibercept)·4D-150 IVT
4D Molecular Therapeutics
Phase 3
480
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Maryland
2025-07-22
Recruiting
A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)
NCT07001280Hereditary Angioedemas
CSL Behring
Observational
200
Arizona, Florida, Illinois, Kentucky, Maryland, Missouri, New Jersey
2025-07-21
Active, closed
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033Primary Myelofibrosis, Myeloproliferative Neoplasm
DrugBesremi
PharmaEssentia
Phase 3
160
California, District of Columbia, Kansas, Maryland, Missouri, New York, North Carolina, Ohio
2025-07-18
Recruiting
Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis
NCT06950385Familial Adenomatous Polyposis (FAP)
DrugERapa
Rapamycin Holdings Inc.
Phase 3
168
California, Connecticut, District of Columbia, Florida, Illinois, Kansas, Maryland, Massachusetts
2025-07-18
Active, closed
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07090330Plaque Psoriasis
DrugORKA-001
Oruka Therapeutics, Inc.
Phase 2
80
California, Connecticut, Florida, Illinois, Kentucky, Maryland, Massachusetts, Michigan
2025-07-18
Recruiting
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
NCT06953089Solid Tumors
DrugsDB-1305/BNT325·Pumitamig
DualityBio Inc.
Phase 2
450
California, Colorado, Florida, Georgia, Maryland, Nebraska, New York, Oregon
2025-07-18
By invitation
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)
NCT06605105Major Depressive Disorder
DrugCYB003
Cybin IRL Limited
Phase 3
468
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts
2025-07-18
Recruiting
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
NCT06824168Acute Myeloid Leukemia, Leukemia
DrugQuizartinib
Daiichi Sankyo
Phase 2
130
Alabama, California, Maryland, Massachusetts, New Jersey, New York, North Carolina, Pennsylvania
2025-07-18
Active, closed
Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms
NCT01064466Small Cell Lung Cancer
DrugETOPOSIDE - Study
Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair
Phase 2/3
600
Maryland
2025-07-16
Recruiting
Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Eye Pressure in Non-Caucasian Patients With Open Angle Glaucoma
NCT07147647Primary Open Angle Glaucoma (POAG)
Select Eye Care
Not applicable
60
Maryland
2025-07-16
Recruiting
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
NCT06996080Macular Edema Secondary to Inflammation
DrugKSI-101
Kodiak Sciences Inc
Phase 3
300
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland
2025-07-16
Recruiting
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
NCT07013474COVID-19 Infection
DrugsIbuzatrelvir·Veklury·Remdesivir
Pfizer
Phase 3
300
California, Colorado, District of Columbia, Florida, Georgia, Idaho, Illinois, Maryland
2025-07-14
Recruiting
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
NCT06764940HER2-negative Breast Cancer Patients With Brain Metastases
DrugsUtidelone·Capecitabine
Biostar Pharma, Inc.
Phase 2
120
California, Colorado, Georgia, Illinois, Maryland, Nevada, New York, Texas
2025-07-14
Recruiting
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
NCT07114874Schizophrenia
DrugNBI-1117568
Neurocrine Biosciences
Phase 3
600
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Mississippi
2025-07-11
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
NCT07011732Alzheimer Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
426
Arizona, California, Colorado, Florida, Louisiana, Maryland, Massachusetts, Michigan
2025-07-10
Active, closed
A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine
NCT07010471Developmental and Epileptic Encephalopathy 1
DrugRelutrigine
Praxis Precision Medicines
Phase 3
160
California, Florida, Maryland, Minnesota, New Jersey, Pennsylvania
2025-07-09
Active, closed
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
NCT06981078Chronic Obstructive Pulmonary Disease
DrugVerekitug
Upstream Bio Inc.
Phase 2
666
California, Florida, Georgia, Illinois, Maryland, Minnesota, North Carolina, South Carolina
2025-07-02
Recruiting
Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old
NCT07049159Shigella
Eveliqure Biotechnologies GmbH
Phase 2
72
Maryland
2025-06-30
Recruiting
Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
NCT07028749Hypertriglyceridemia
DrugMAR001
Marea Therapeutics
Phase 2
316
Alabama, Arkansas, Connecticut, Florida, Georgia, Illinois, Kentucky, Maryland
2025-06-30
Recruiting
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06995677Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration
DrugTYRA-300
Tyra Biosciences, Inc
Phase 2
90
Alabama, Arkansas, California, Illinois, Indiana, Kansas, Maryland, Massachusetts
2025-06-27
Recruiting
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
NCT06665100Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT)
Pulmotect, Inc.
Phase 2
100
California, Georgia, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New York
2025-06-27
By invitation
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
NCT07008469Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy, Myotonia
Avidity Biosciences, Inc.
Phase 3
199
California, Colorado, Florida, Indiana, Kansas, Maryland, Massachusetts, Minnesota
2025-06-26
Recruiting
REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
NCT07015905Venous Thromboembolism (VTE)
DrugsCenvacibart·Enoxaparin·Apixaban
Regeneron Pharmaceuticals
Phase 3
2,000
Alabama, California, Colorado, Florida, Maryland, Massachusetts, New Jersey, North Carolina
2025-06-25
Recruiting
An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
NCT07033026Colorectal Cancer, CRC (Colorectal Cancer), Cancer Cachexia
NGM Biopharmaceuticals, Inc
Phase 2
136
California, Florida, Maryland, New York, Ohio, Texas, Virginia, Wisconsin
2025-06-25
Recruiting
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT07020221Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult
DrugsVS-7375·Erbitux·Cetuximab·Nab-paclitaxel
Verastem, Inc.
Phase 1/2
295
California, Maryland, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Tennessee
2025-06-24
Recruiting
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281Relapsing Multiple Sclerosis
DrugsRemibrutinib·Ocrelizumab
Novartis Pharmaceuticals
Phase 3
400
Arizona, California, District of Columbia, Florida, Illinois, Kansas, Maryland, Massachusetts
2025-06-23
Active, closed
Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms
NCT06062810Breast Cancer
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Phase 2/3
600
Maryland
2025-06-21
By invitation
Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia
NCT07073014Hypochondroplasia
DrugVosoritide
BioMarin Pharmaceutical
Phase 3
140
Arizona, California, Delaware, District of Columbia, Illinois, Maryland, Minnesota, Missouri
2025-06-20
Recruiting
Clinical Performance Evaluation of Native Whole Blood Samples of Patients on DOACs With the Perosphere ClotChek™
NCT07012291Coagulation
Perosphere Technologies Inc.
Observational
150
Connecticut, Maryland, New Jersey, New York
2025-06-20
Recruiting
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
NCT06959095Pulmonary Disease, Chronic Obstructive
DrugDepemokimab
GlaxoSmithKline
Phase 3
981
California, Delaware, Florida, Georgia, Illinois, Maryland, Michigan, Missouri
2025-06-20
Recruiting
Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance
NCT06658730Vascular Disease, Dissection, Dissection Aortic Aneurysm, Dissection of Aorta
W.L.Gore & Associates
Observational
1,500
Arizona, California, District of Columbia, Florida, Georgia, Indiana, Maryland, Massachusetts
2025-06-19
Recruiting
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
NCT06991257Heart Failure
DrugPF-07328948
Pfizer
Phase 2
620
California, Florida, Illinois, Indiana, Maryland, Nebraska, Ohio, Texas
2025-06-19
Recruiting
First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer
NCT06934538Unresectable Metastatic Colorectal Cancer, Unresectable Locally Advanced Colorectal Cancer
Brenus Pharma
Phase 1/2
90
Maryland
2025-06-17
Active, closed
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
NCT06832618Atopic Dermatitis
DrugRuxolitinib
Incyte Corporation
Phase 3
159
Alabama, Arizona, Colorado, Florida, Georgia, Idaho, Illinois, Maryland
2025-06-17
Active, closed
An Observational Study of Individuals With Isolated Dystonia
NCT07111663Isolated/Primary Dystonia That Affects More Than One Region of the Body
Vima Therapeutics
Observational
200
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Michigan
2025-06-17
Recruiting
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients
NCT07051629Epilepsy, Healthy Volunteer
Suninflam Inc
Phase 1
88
Arizona, Florida, Hawaii, Maryland, Michigan, New York, North Carolina, Texas
2025-06-16
Recruiting
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)
NCT06789913PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations, Vascular Malformations, PIK3CA Mutation
DrugRLY-2608
Relay Therapeutics, Inc.
Phase 2
277
Arizona, Arkansas, California, Colorado, Georgia, Indiana, Iowa, Maryland
2025-06-13
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
NCT06951711Bipolar Disorder Type I With Mania or Mania With Mixed Features
DrugKarXT
Bristol-Myers Squibb
Phase 3
274
Arkansas, California, Florida, Georgia, Illinois, Maryland, Mississippi, Missouri
2025-06-13
Recruiting
Examination of Nociscan Impact on Low Back Pain Surgical Outcomes
NCT06661850Low Back Pain
Aclarion
Observational
300
Arizona, California, Florida, Illinois, Maryland, Texas
2025-06-11
Recruiting
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
NCT07038200Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1
DrugDel-brax
Avidity Biosciences, Inc.
Phase 3
200
California, Colorado, Florida, Iowa, Kansas, Maryland, Massachusetts, New York
2025-06-10
Recruiting
Safety and Tolerability of a Novel Implantable Device for the Treatment of Erectile Dysfunction
NCT06968494Erectile Dysfunction Following Radical Prostatectomy
Comphya Inc.
Not applicable
20
Maryland
2025-06-05
Recruiting
A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity
NCT07013643Healthy Participants
DrugsAZD9550·Lenbelintide·Acetaminophen
AstraZeneca
Phase 1
50
California, Maryland
2025-06-04
Not yet open
Study to Evaluate the Safety, Tolerability, and Efficacy of PEP-TISSEEL in Subjects With Chronic Radiation Ulcer
NCT06793748Chronic Radiation Ulcer
Rion Inc.
Phase 1/2
184
Maryland
2025-06
Active, closed
A Data Collection Protocol to Evaluate the Real World Usage of the Orthofix AccelStim Device to Treat Fresh Metatarsal Fractures
NCT07286357Metatarsal Fracture
Orthofix Inc.
Observational
100
Illinois, Maryland
2025-05-30
Recruiting
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06963021Major Depressive Disorder
DrugNBI-1065845
Neurocrine Biosciences
Phase 3
200
California, Colorado, Connecticut, Florida, Maryland, New York, North Carolina, Pennsylvania
2025-05-30
Recruiting
Effectiveness of the WearME System for COPD Severity and Respiratory Function
NCT06751537Chronic Obstructive Pulmonary Disease (COPD)
LASARRUS Clinic and Research Center
Observational
128
Maryland
2025-05-29
Active, closed
A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.
NCT06917404Osteoarthritis, Knee
DrugPentosan Polysulfate Sodium
Paradigm Biopharmaceuticals Ltd.
Phase 3
466
Arizona, California, Florida, Illinois, Maryland, Michigan, Nebraska, Nevada
2025-05-29
Recruiting
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
NCT06764615Crohn's Disease, Ulcerative Colitis
DrugZasocitinib
Takeda
Phase 2
192
Maryland, Texas
2025-05-28
Recruiting
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
NCT06780098Lung Neoplasm
DrugsR-DXd·Ifinatamab Deruxtecan·Taxotere·Docetaxel
Merck Sharp & Dohme LLC
Phase 2
144
Kentucky, Maryland, Texas, Virginia
2025-05-28
Recruiting
Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer
NCT05918783Peripheral Lung Tumor
Impact Biotech Ltd
Phase 1
36
Maryland
2025-05-28
Recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia
NCT06980428Healthy Participants, Dyslipidemia
AstraZeneca
Phase 1
136
California, Florida, Maryland, Texas
2025-05-27
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
California, Colorado, Florida, Illinois, Kansas, Kentucky, Louisiana, Maryland
2025-05-27
Recruiting
Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients
NCT06395285ROSAH
DrugDF-003
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)
Phase 1
12
Maryland, North Carolina, Utah
2025-05-27
Recruiting
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
NCT06697301Advanced Melanoma
DrugsEIK1001·Keytruda·Pembrolizumab
Eikon Therapeutics
Phase 2/3
740
Arizona, Arkansas, California, Colorado, Florida, Maryland, Missouri, Ohio
2025-05-22
Active, closed
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
NCT06966479Severe Asthma
DrugVerekitug
Upstream Bio Inc.
Phase 2
396
California, Florida, Idaho, Maryland, Michigan, Nevada, New York, Ohio
2025-05-21
Recruiting
Pelacarsen Roll-over Extension Program
NCT06875973Atherosclerotic Cardiovascular Disease
DrugPelacarsen
Novartis Pharmaceuticals
Phase 3
599
Alabama, Arkansas, California, Florida, Georgia, Illinois, Louisiana, Maryland
2025-05-19
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472Obesity, Overweight, Type 2 Diabetes
DrugOrforglipron
Eli Lilly and Company
Phase 3
600
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-19
Active, closed
Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix
NCT03305341Covid19
DrugBCG Vaccine Mix for percutaneous use
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Phase EARLY_PHASE1
20
Maryland
2025-05-18
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459Obesity, Overweight
DrugOrforglipron
Eli Lilly and Company
Phase 3
800
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-15
Recruiting
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
NCT06990867Acute Ischemic Stroke
Corxel Pharmaceuticals
Phase 2/3
740
California, Colorado, District of Columbia, Florida, Illinois, Kansas, Maryland, Michigan
2025-05-15
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792Obesity, Overweight, Type 2 Diabetes
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,400
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-15
Recruiting
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
NCT07003425Atopic Dermatitis
DrugAPG777
Apogee Therapeutics, Inc.
Phase 2
350
California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan, New York
2025-05-14
Recruiting
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
NCT06822426Central Line Associated Blood Stream Infections (CLABSI)
Drugs(taurolidine and heparin) catheter lock·Heparin
CorMedix Therapeutics
Phase 3
200
California, District of Columbia, Florida, Georgia, Illinois, Iowa, Maryland, Minnesota
2025-05-14
Recruiting
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
NCT06780085Carcinoma, Non-Small-Cell Lung
DrugsR-DXd·Ifinatamab Deruxtecan
Merck Sharp & Dohme LLC
Phase 2
96
Kentucky, Maryland, Pennsylvania
2025-05-13
Recruiting
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06801236Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)
Acerand Therapeutics (Hong Kong) Limited
Phase 1
88
California, Florida, Maryland, Massachusetts, Minnesota, Nebraska, South Carolina, Washington
2025-05-12
Recruiting
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies
DrugAcoramidis
Eidos Therapeutics, a BridgeBio company
Phase 3
587
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Maryland
2025-05-12
Recruiting
EXoPERT EMERALD Clinical Study
NCT07186296Breast Cancer, Colon Cancer, Pancreatic Cancer, Ovarian Cancer
EXoPERT
Observational
1,400
California, Hawaii, Kentucky, Maryland, New York
2025-05-09
Recruiting
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
NCT06963034Schizophrenia
DrugNBI-1117568
Neurocrine Biosciences
Phase 3
284
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, New Jersey
2025-05-08
Active, closed
A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy
NCT06907875Facioscapulohumeral Muscular Dystrophy
Epicrispr Biotechnologies, Inc.
Phase 1/2
12
California, Georgia, Maryland, Massachusetts, Utah
2025-05-08
Recruiting
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
NCT06952699Narcolepsy Type 2
DrugTAK-360
Takeda
Phase 2
88
Alabama, Arizona, California, Colorado, Florida, Georgia, Maryland, Michigan
2025-05-06
Recruiting
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT06499285Myelodysplastic Syndromes
DrugElritercept
Takeda
Phase 3
225
California, Connecticut, Florida, Illinois, Kentucky, Maryland, Missouri, Nevada
2025-05-06
Recruiting
Safety of HRX215 in Patients After Minor and Major Liver Resection
NCT06638502Liver Resection, Colorectal Carcinoma Liver Metastases
HepaRegeniX GmbH
Phase 1/2
80
Maryland, Minnesota, North Carolina, Ohio
2025-05-06
Recruiting
Motiva Implants® Post-Approval Study
NCT06938399Breast Implant
Motiva USA LLC
Not applicable
2,400
California, Colorado, District of Columbia, Florida, Illinois, Kentucky, Louisiana, Maryland
2025-05-01
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530Hypertension
DrugOrforglipron
Eli Lilly and Company
Phase 3
487
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422Hypertension
DrugOrforglipron
Eli Lilly and Company
Phase 3
974
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435Hypertension, Overweight or Obesity
DrugOrforglipron
Eli Lilly and Company
Phase 3
487
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Recruiting
A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects
NCT05913752Alcohol Use Disorder
Clearmind Medicine Inc.
Phase 1/2
84
Connecticut, Maryland
2025-04-30
Recruiting
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
NCT06813911Atherosclerotic Cardiovascular Disease (ASCVD)
DrugsPelacarsen·Inclisiran
Novartis Pharmaceuticals
Phase 3
340
Alabama, Arizona, California, Florida, Illinois, Indiana, Louisiana, Maryland
2025-04-30
Recruiting
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
NCT06394869Hematuria - Cause Not Known
Pacific Edge Limited
Not applicable
1,000
Alabama, California, Florida, Indiana, Louisiana, Maryland, New Jersey, New York
2025-04-29
Active, closed
Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation
NCT06990529PIDs Linked to PI3K
DrugLeniolisib
Pharming Technologies B.V.
Phase 2
12
Maryland, Massachusetts, New York
2025-04-29
Active, closed
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV
NCT06959563HPV Infection
DrugsBCG Vaccine Mix for percutaneous use·Nonavalent HPV vaccine
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Phase EARLY_PHASE1
20
Maryland
2025-04-28
Recruiting
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06624085Lymphoma
DrugsGlofitamab·Tocilizumab·Obinutuzumab·Oxaliplatin
Hoffmann-La Roche
Phase 1
50
California, District of Columbia, Florida, Georgia, Illinois, Kansas, Maryland, New Mexico
2025-04-28
Recruiting
First-in-Human Single and Multiple Dose of HL-400
NCT06997484Parkinson Disease
Highlightll Pharmaceutical (USA) LLC
Phase 1
86
Maryland
2025-04-25
Recruiting
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
NCT06915753Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification
Tyra Biosciences, Inc
Phase 1
125
California, Kansas, Maryland, Massachusetts, Michigan, New York, Tennessee
2025-04-24
By invitation
An Interventional Study of Infigratinib in Children With Hypochondroplasia
NCT06873035Hypochondroplasia
DrugInfigratinib
QED Therapeutics, a BridgeBio company
Phase 2/3
24
California, Colorado, District of Columbia, Maryland, Missouri, Ohio, Tennessee, Wisconsin
2025-04-22
Recruiting
Auryon Atherectomy System With Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone
NCT06777901Peripheral Arterial Diseases
Angiodynamics, Inc.
Phase 4
224
Arizona, California, Louisiana, Maryland, Massachusetts, Missouri, North Carolina, Ohio
2025-04-21
Recruiting
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
NCT06897930Lupus Erythematosus, Systemic
DrugsAZD0120·Fludarabine·Cyclophosphamide
AstraZeneca
Phase 1/2
150
California, Florida, Georgia, Illinois, Maryland, Massachusetts, Missouri, New York
2025-04-21
Active, closed
Pivotal Study of Voro Urologic Scaffold
NCT06873581Radical Prostatectomy, Stress Urinary Incontinence (SUI)
Levee Medical, Inc.
Phase 3
266
Arizona, California, Florida, Illinois, Indiana, Maryland, Mississippi, New York
2025-04-18
Recruiting
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
NCT06951217Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc.
Phase 2
340
Alabama, California, Colorado, Connecticut, Florida, Georgia, Kansas, Maryland
2025-04-17
Recruiting
Fertilo In Vitro Research Study and Trial
NCT06858111In Vitro Maturation of Oocytes
Gameto, Inc.
Phase 3
500
California, Florida, Maryland, New York, North Carolina, Texas, Utah
2025-04-17
Recruiting
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401Major Depressive Disorder
DrugNBI-1065845
Neurocrine Biosciences
Phase 3
850
Alabama, Arkansas, California, Connecticut, Florida, Georgia, Maryland, Massachusetts
2025-04-16
Active, closed
A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)
NCT06941844Major Depressive Disorder
DrugDT120
Definium Therapeutics US, Inc.
Phase 3
149
Arkansas, California, Colorado, Florida, Illinois, Maryland, Massachusetts, Missouri
2025-04-14
Recruiting
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
NCT07327489Cancer, Immunotherapy, Advanced Solid Tumors Cancer, Bladder Cancer
Elephas
Observational
2,000
Arkansas, Maryland, Missouri, Oklahoma, Texas
2025-04-14
Recruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
NCT06865105Psoriatic Arthritis
DrugsLutikizumab·Risankizumab
AbbVie
Phase 2
120
California, Florida, Illinois, Maryland, Ohio, Pennsylvania, Tennessee, Texas
2025-04-11
Recruiting
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06846671CLL, Chronic Lymphocytic Leukemia
DrugsIdelalisib·Tacabrutideg·Bendamustine·Venetoclax
BeOne Medicines
Phase 3
250
Arkansas, California, Colorado, Florida, Georgia, Louisiana, Maryland, Michigan
2025-04-10
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693Breast Cancer
DrugsCDK4/6i·Inavolisib·Letrozole
Hoffmann-La Roche
Phase 3
450
Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan
2025-04-09
Active, closed
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
NCT06822790Hypertriglyceridemia
DrugPlozasiran
Arrowhead Pharmaceuticals
Phase 3
710
California, Florida, Georgia, Illinois, Indiana, Kansas, Maryland, Michigan
2025-04-09
Recruiting
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
NCT06920043Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
GlaxoSmithKline
Phase 2
42
Arizona, California, Florida, Georgia, Maryland, Missouri, New York, North Carolina
2025-04-09
Recruiting
Tissue Reinforcement for Breast Reconstruction (TRBR) Pivotal Clinical Study (REDEFINE)
NCT06556654Breast Reconstruction Surgery
W.L.Gore & Associates
Not applicable
180
Arizona, California, Florida, Illinois, Kansas, Maryland, Michigan, Mississippi
2025-04-09
Active, closed
Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection
NCT06621251Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee
Trellis Bioscience LLC
Phase 2
60
Arizona, California, Florida, Maryland, Massachusetts, New York, North Carolina, Texas
2025-04-08
Recruiting
CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)
NCT06708299Recurrent Pericarditis
Cardiol Therapeutics Inc.
Phase 3
110
Arizona, California, Florida, Illinois, Maryland, Massachusetts, Minnesota, New York
2025-04-07
Recruiting
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
NCT06731907Non-small Cell Lung Cancer
DrugsPatritumab deruxtecan·Abraxane·Paraplatin·Taxol
Merck Sharp & Dohme LLC
Phase 2
90
Kentucky, Maryland, North Dakota, Pennsylvania, South Dakota
2025-03-30
By invitation
Study Evaluating Xtressé Gummy Supplement in Women With Self-Perceived Thinning Hair
NCT07224555Hair Thinning
Restore Biologics Holdings, Inc. dba Xtressé
Not applicable
60
Florida, Georgia, Maryland, Washington
2025-03-27
Active, closed
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
NCT06818812Solid Tumors
DrugsGEMNabP·MFOLFIRINOX·Cetuximab
Incyte Corporation
Phase 1
30
California, Colorado, District of Columbia, Florida, Maryland, New Jersey, Pennsylvania, Tennessee
2025-03-27
Recruiting
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
NCT06795022Hepatocellular Carcinoma
AstraZeneca
Phase 1/2
304
California, Maryland, Massachusetts, Missouri, New Jersey, Texas
2025-03-27
Active, closed
A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection
NCT06907290Chronic Hepatitis D Infection
DrugBulevirtide
Mirum Pharmaceuticals, Inc.
Phase 2/3
150
California, Florida, Illinois, Iowa, Maryland, Massachusetts, New York, Pennsylvania
2025-03-25
Recruiting
A Comparison of NeuroSpan Bridge, NeuraGen Nerve Guide, and Nerve Autograft for Peripheral Nerve Repair
NCT06529835Peripheral Nerve Injuries
Auxilium Biotechnologies
Not applicable
80
California, Maryland, New York, Ohio, Pennsylvania, Texas
2025-03-21
Recruiting
Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis
NCT06911424Bacterial Conjunctivitis
Baxis Pharmaceuticals, Inc.
Phase 3
400
Arkansas, California, Florida, Georgia, Idaho, Illinois, Maryland, Nevada
2025-03-21
Active, closed
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
NCT06788912Lung Neoplasm Malignant
DrugsSteroid mouthwash (dexamethasone·Acetaminophen·Ribociclib·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 2
60
Alabama, California, Colorado, Maryland, Oregon, Texas, Virginia
2025-03-20
Active, closed
A Study of Navenibart in Participants With Hereditary Angioedema
NCT06842823Hereditary Angioedema (HAE)
DrugNavenibart
Astria Therapeutics, Inc.
Phase 3
157
Alabama, Arizona, Arkansas, California, Colorado, Florida, Maryland, Massachusetts
2025-03-20
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007Ovarian Cancer
DrugsTrastuzumab deruxtecan·Bevacizumab
Daiichi Sankyo
Phase 3
582
California, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland, Massachusetts
2025-03-19
Recruiting
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
NCT06857942Psoriasis, Overweight or Obesity
DrugTirzepatide
Eli Lilly and Company
Phase 4
200
Arizona, California, Florida, Georgia, Indiana, Kentucky, Maryland, Massachusetts
2025-03-19
By invitation
An Open-Label Study of Azetukalner in Major Depressive Disorder
NCT06922110Major Depressive Disorder
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
460
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland
2025-03-18
Recruiting
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
NCT06792695Metastatic Colorectal Cancer
DrugsFOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)·Volrustomig·Bevacizumab
AstraZeneca
Phase 2
80
Arizona, California, District of Columbia, Illinois, Maryland, Massachusetts, Minnesota, New Jersey
2025-03-12
Active, closed
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
NCT06903338Viral Hepatitis
DrugsTobevibart·Elebsiran
Vir Biotechnology, Inc.
Phase 3
124
Arizona, California, Florida, Illinois, Maryland, New Jersey, New York, Utah
2025-03-12
Recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496Psoriatic Arthritis
DrugZasocitinib
Takeda
Phase 3
600
Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan
2025-03-10
Active, closed
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
NCT06736418Small-Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung
Abdera Therapeutics Inc.
Phase 1
17
California, Florida, Maryland, Massachusetts, Minnesota, New York, Texas, Utah
2025-03-10
Active, closed
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
NCT06864026Psoriatic Arthritis, Overweight or Obesity
DrugTirzepatide
Eli Lilly and Company
Phase 4
200
Arizona, California, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland
2025-03-06
Recruiting
Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1
NCT06714253Radiation-Induced Xerostomia and Hyposalivation
RiboX Therapeutics Ltd.
Phase 1/2
42
California, Iowa, Maryland, New York, Pennsylvania
2025-03-05
Active, closed
Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease
NCT06824987APOL1-Mediated Kidney Disease
AstraZeneca
Phase 2
57
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland
2025-03-05
Recruiting
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
NCT06842355Achondroplasia
DrugTYRA-300
Tyra Biosciences, Inc
Phase 2
92
California, Colorado, Delaware, Maryland, Missouri, North Carolina, Tennessee, Texas
2025-03-04
Active, closed
Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
NCT06840483Breast Cancer
DrugZelenectide pevedotin
BicycleTx Limited
Phase 2
66
Maryland, Massachusetts, Missouri, New York, North Carolina, Oregon, Texas, Virginia
2025-03-03
Recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483Psoriatic Arthritis
DrugZasocitinib
Takeda
Phase 3
1,088
Arizona, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2025-03-03
Active, closed
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
NCT06894212Schizophrenia
DrugUlotaront
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
538
Arkansas, California, Florida, Georgia, Illinois, Louisiana, Maryland, New Jersey
2025-02-28
Active, closed
A Phase 2 in Adult Subjects With Hereditary Angioedema
NCT06846398Hereditary Angioedema (HAE)
DrugBW-20805
Shanghai Argo Biopharmaceutical Co., Ltd.
Phase 2
25
Maryland, Missouri, North Carolina, Pennsylvania, Virginia
2025-02-28
Recruiting
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
NCT06778863Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma
Clasp Therapeutics, Inc.
Phase 1
90
Arizona, California, Florida, Illinois, Kentucky, Maryland, New Jersey, New York
2025-02-28
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer
DrugsTrastuzumab deruxtecan·Trastuzumab·Keytruda·Pembrolizumab
Daiichi Sankyo
Phase 3
726
Connecticut, Illinois, Kansas, Maryland, Massachusetts, Michigan, Minnesota, New York
2025-02-27
Recruiting
A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee
NCT06884865Osteoarthritis (OA) of the Knee
Pacira Pharmaceuticals, Inc
Phase 2
135
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland
2025-02-26
Recruiting
Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant
NCT06938867E Coli Infections, Allogenic Transplant Patients
SNIPR Biome Aps.
Phase 1/2
24
California, Maryland, Minnesota, New York, Pennsylvania, Texas, Washington
2025-02-25
Recruiting
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
NCT06847321Alzheimer Disease, Alzheimer Disease Due to P. Gingivalis
Lighthouse Pharmaceuticals, Inc.
Phase 2
300
Arizona, California, Colorado, Florida, Georgia, Kansas, Louisiana, Maryland
2025-02-17
Recruiting
OurRelationship-S: A Digital Relationship-Strengthening Program for Couples Experiencing Substance Misuse
NCT07159633Relationship Conflict, Relationship Distress
OurRelationship
Not applicable
120
Georgia, Maryland, New York, South Carolina, Texas
2025-02-15
Recruiting
IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers
NCT06616844Wound Heal, Ulcer
ConvaTec Inc.
Not applicable
235
California, Florida, Indiana, Maryland, Massachusetts, New York, North Carolina, Pennsylvania
2025-02-12
By invitation
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
NCT06908226Developmental and Epileptic Encephalopathy
DrugBexicaserin
Longboard Pharmaceuticals
Phase 3
324
Arkansas, California, Colorado, Florida, Idaho, Maryland, Massachusetts, Minnesota
2025-02-12
Active, closed
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
NCT06770933Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
Vantage Biosciences Ltd
Phase 2
100
California, Florida, Georgia, Maryland, Oregon, Pennsylvania, Virginia
2025-02-11
Recruiting
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
NCT06541847Neurofibromatosis Type 1
Healx Limited
Phase 2
25
Alabama, California, Colorado, District of Columbia, Illinois, Indiana, Maryland, Missouri
2025-02-10
Recruiting
This Study Will Evaluate the Effectiveness of NTX-001, a Surgical Nerve Repair Product When Used in People With Upper Extremity Nerve Lacerations.
NCT06616025Peripheral Nerve Injury Upper Limb, Peripheral Nerve Injury (PNI)
Neuraptive Therapeutics Inc.
Phase 3
98
California, Florida, Georgia, Illinois, Kentucky, Louisiana, Maryland, Missouri
2025-02-10
Recruiting
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
NCT06785636mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostate Cancer
Pathos AI, Inc.
Phase 1/2
120
California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland
2025-02-07
Active, closed
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920Generalized Myasthenia Gravis
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
180
Arizona, California, District of Columbia, Florida, Illinois, Maryland, Massachusetts, Michigan
2025-02-07
Active, closed
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834360Chronic Rhinosinusitis With Nasal Polyps
DrugsItepekimab·Mometasone furoate
Sanofi
Phase 3
216
Alabama, California, Florida, Illinois, Kentucky, Louisiana, Maryland, Ohio
2025-02-06
Recruiting
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NCT06556563Glioblastoma
DrugsTemozolomide·Keytruda·Pembrolizumab
NovoCure GmbH
Phase 3
741
Arizona, California, District of Columbia, Florida, Illinois, Kentucky, Maryland, Massachusetts
2025-02-03
Active, closed
WATER IV Prostate Cancer
NCT06651632Localized Prostate Cancer
PROCEPT BioRobotics
Not applicable
280
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Maryland
2025-02-03
Recruiting
Integrity Implant System Post Market Clinical Follow-Up Study
NCT06741527Rotator Cuff Tears of the Shoulder
Anika Therapeutics, Inc.
Not applicable
150
Arizona, California, Florida, Georgia, Indiana, Maryland, New Jersey, South Carolina
2025-02-01
Recruiting
A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
NCT06842186Overweight and Obesity
Wave Life Sciences USA, Inc.
Phase 1/2
296
Maryland
2025-01-31
Active, closed
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
NCT06809595Generalized Anxiety Disorder
DrugDT120
Definium Therapeutics US, Inc.
Phase 3
245
Arkansas, California, Florida, Georgia, Maryland, Massachusetts, New Jersey, Ohio
2025-01-29
Active, closed
Orthofix PhysioStim PEMF Ankle Fusion Retrospective
NCT07282067Ankle Fusion, Hindfoot Arthrodesis, Ankle Arthrodesis, Tibiotalar Arthrodesis
Orthofix Inc.
Observational
200
Arizona, California, Iowa, Maryland, North Carolina, Texas
2025-01-23
Recruiting
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
NCT06517888Vestibular Schwannoma
Akouos, Inc.
Phase 1/2
27
Maryland, Minnesota, Tennessee, Texas
2025-01-17
Recruiting
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126Melanoma, Cutaneous Malignant
DrugsAnzu-cel·Lifileucel·Temodar·Dacarbazine
Immatics US, Inc.
Phase 3
360
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Maryland
2025-01-14
Recruiting
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
NCT06659549Geographic Atrophy of the Macula
Galimedix Therapeutics Inc
Phase 2
110
California, Maryland
2025-01-10
Rows per page Showing 1–500 of 1268
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-usa/state/maryland

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,118 studies in total at the last sync on 06 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,268 of those studies with a site in Maryland.

How many clinical trials are recruiting in Maryland?

648 of the 1,268 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:16 UTC sync. A further 34 have not yet opened recruitment, 545 are active but closed to new participants, and 41 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Maryland), 1,268 studies
PhaseStudiesRecruitingShare
Phase 340719032.1%
Phase 228414922.4%
Phase 11368210.7%
Observational1347110.6%
Phase 1/2122699.6%
Not applicable121569.5%
Phase 2/337192.9%
Phase 423111.8%
Phase EARLY_PHASE1410.3%

Most active sponsors

Lead sponsors with the most studies (Maryland)
Lead sponsorStudiesRecruiting
AstraZeneca7838
Novartis Pharmaceuticals3117
Merck Sharp & Dohme LLC2920
Eli Lilly and Company2814
Pfizer2716
Bristol-Myers Squibb2614
Janssen Research & Development, LLC2111
AbbVie208
Hoffmann-La Roche204
Takeda1713
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.